-
1Academic Journal
Πηγή: Высшая школа: научные исследования.
Θεματικοί όροι: ДГПЖ, хирургическое лечение, Доброкачественная гиперплазия предстательной железы, трансуретральная резекция предстательной железы, ТУР ПЖ
-
2Academic Journal
Συγγραφείς: Z. Sh. Pavlova, I. A. Orlova, A. A. Kamalov, З. Ш. Павлова, Я. А. Орлова, А. А. Камалов
Συνεισφορές: The authors declare no funding, Авторы заявляют об отсутствии финансовой поддержки
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 19, No 5 (2025); 776-787 ; Акушерство, Гинекология и Репродукция; Vol 19, No 5 (2025); 776-787 ; 2500-3194 ; 2313-7347
Θεματικοί όροι: мужчины, benign prostatic hyperplasia, BPH, testosterone, estradiol, men, доброкачественная гиперплазия предстательной железы, ДГПЖ, тестостерон, эстрадиол
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/2529/1399; Cannarella R., Condorelli R.A., Barbagallo F. et al. Endocrinology of the aging prostate: current concepts. Front Endocrinol (Laussane). 2021;12:554078. https://doi.org/10.3389/fendo.2021.554078.; Vuichoud C., Loughlin K.R. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015;22(Suppl 1):1–6.; Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. https://doi.org/10.3322/caac.21332.; De Santis C.E., Siegel R.L., Sauer A.G. et al. Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin. 2016;66(4):290–308. https://doi.org/10.3322/caac.21340.; Rohrmann S., Nelson W.G., Rifai N. et al. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab. 2007;92(7):2519–25. https://doi.org/10.1210/jc.2007-0028.; Williams V.L., Awasthi S., Fink A.K. et al. African-American men and prostate cancer-specific mortality: a competing risk analysis of a large institutional cohort, 1989-2015. Cancer Med. 2018;7(5):2160–71. https://doi.org/10.1002/cam4.1451.; Каприн А.Д., Алексеев Б.Я., Матвеев В.Б. и др. Рак предстательной железы. Клинические рекомендации. Современная oнкология. 2021;23(2):211–47. https://doi.org/10.26442/18151434.2021.2.200959.; Rider J.R., Wilson K.W., Sinnott J.A. et al. Ejaculation frequency and risk of prostate cancer: updated results with an additional decade of follow-up. Eur Urol. 2016;70(6):974–82. https://doi.org/10.1016/j.eururo.2016.03.027.; Pernar C.H., Ebot E.M., Wilson K.M., Mucci L.A. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018;8(12):a030361. https://doi.org/10.1101/cshperspect.a030361.; Дедов И.И., Мельниченко Г.А., Фадеев В.Ф. Руководство по эндокринологии. M.: ГЭОТАР-Медиа, 2007. 432 с.; Зильбер А.П. Синдромы сонного апноэ: клиническая физиология, лечение, профилактика. Петрозаводск: Изд-во Петрозаводского университета, 1994. 184 с.; Al-Shboul O.A., Mustafa A.G., Omar A.A. et al. Effect of progesterone on nitric oxide/cyclic guanosine monophosphate signaling and contraction in gastric smooth muscle cells. Biomed Rep. 2018;9(6):511–6. https://doi.org/10.3892/br.2019.1251.; Alqudah M., Al-Shboul O., Al Dwairi A. et al. Progesterone inhibitory role on gastrointestinal motility. Physiol Res. 2022;71(2):193–8. https://doi.org/10.33549/physiolres.934824.; Shackleton C., Malunowicz E. Apparent pregnene hydroxylation deficiency (APDH): seekingthe parentage of an orphan metabolome. Steroids. 2003;68(9):707–17. https://doi.org/10.1016/s0039-128x(03)00115-6.; Oettel M., Mukhopadhyay A.K. Progesterone: the forgotten hormone in man. Aging Male. 2004;7(3):236–57. https://doi.org/10.1080/13685530400004199.; Федотчева Т.А. Клиническое применение прогестинов и механизмы их действия: настоящее и будущее (обзор). Современные технологии в медицине. 2021;13(1):93–108. https://doi.org/10.17691/stm2021.13.1.11.; Graham J.D., Clarcke C.L. Physiological action of progesterone in target tissues. Endocr Rev. 1997;18(4):502–19. https://doi.org/10.1210/edrv.18.4.0308.; Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8 Suppl 1:3–63. https://doi.org/10.1080/13697130500148875.; Якушевская О.В. Современные подходы к назначению прогестерона в практике акушера-гинеколога. Эффективная фармакотерапия. Акушерство и гинекология. 2012;(4):12–6.; Baranizadeh K., Mahboobian M.M., Amiri I. et al. Effects of progesterone nanoparticles on the sperm capacitation and acrosome reaction in asthenozoospermia men. Andrologia. 2022;54(1):e14258. https://doi.org/10.1111/and.14258.; Sutter-Dub M. Rapid non-genomic and genomic responses to progestogens, estrogens, and glucocorticoids in the endocrine pancreatic B cell, the adipocyte and other cell types. Steroids. 2002;67(2):77–93. https://doi.org/10.1016/s0039-128x(01)00142-8.; Ghandehari S., Matusov Y., Pepkowitz S. et al. Progesterone in addition to standard of care vs standard of care alone in the treatment of men hospitalized with moderate to severe COVID-19: a randomized, controlled pilot trial. Chest. 2021;160(1):74–84. https://doi.org/10.1016/j.chest.2021.02.024.; Beltrame A., Salguero P., Rossi E. et al. Immunometabolic mechanisms underlying the severity of COVID-19. Viral Immunol. 2022;13:1–10. https://doi.org/10.3389/fimmu.2022.834851.; Mauvais-Jarvis F., Klein S.L., Levin E.R. Estradiol, progesterone, immunomodulation, and COVID-19 outcomes. Endocrinology. 2020;161(9):bqaa127. https://doi.org/10.1210/endocr/bqaa127.; Physicians desk reference. Montvale N.J.: Thomson P.D.R., 2006. 60th ed. 3529 p.; Garg D., Ng S.S.M., Baig K.M. et al. Progesterone-mediated non-classical signaling. Trends Endocrinol Metab. 2017;28(9):656–68. https://doi.org/10.1016/j.tem.2017.05.006.; Wetendorf M., DeMayo F.J. Progesterone receptor signaling in the initiation of pregnancy and preservation of a healthy uterus. Int J Dev Biol. 2014;58(2–4):95–106. https://doi.org/10.1387/ijdb.140069mw.; Valadez-Cosmes P., Vázquez-Martínez E.R., Cerbon M., Camacho-Arroyo I. Membrane progesterone receptors in reproduction and cancer. Mol Cell Endocrinol. 2016;434:166–75. https://doi.org/10.1016/j.mce.2016.06.027.; Kolatorova L., Vitku J., Suchopar J. et al. Progesterone: a steroid with wide range of effects in physiology as well as human medicine. Int J Mol Sci. 2022;23(14):7989. https://doi.org/10.3390/ijms23147989.; Haseroth K., Christ M., Falkenstein E., Wehling M. Aldosterone- and progesterone-membrane-binding proteins: new concepts of nongenomic steroid action. Curr Protein Pept Sci. 2000;1(4):385–401. https://doi.org/10.2174/1389203003381270.; Falkenstein E., Heck M., Gerdes D. et al. Specific progesterone binding to a membrane protein and related nongenomic effects on Ca2+-fluxes in sperm. Endocrinology. 1999;140(12):5999–6002. https://doi.org/10.1210/endo.140.12.7304.; Falkenstein E., Tillmann H.C., Christ M. et al. Multiple actions of steroid hormones-a focus on rapid, nongenomic effects. Pharmacol Rev. 2000;52(4):513–56. https://doi.org/10.1016/S0031-6997(24)01468-6.; Simoncini T., Genazzani A.R. Non-genomic actions of sex steroid hormones. Eur J Endocrinol. 2003;148(3):281–92. https://doi.org/10.1530/eje.0.1480281.; Conneely O.M., Lydon J.P. Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids. 2000;65(10–11):571–7. https://doi.org/10.1016/s0039-128x(00)00115-x.; Cassidenti D.L., Paulson R.J., Serafini P. et al. Effects of sex steroids on skin 5 alpha-reductase activity in vitro. Obstet Gynecol. 1991;78(1):103–7.; Hou Z., Huang S., Mei Z. et al. Inhibiting 3βHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer. Cell Rep Med. 2022;3(3):100561. https://doi.org/10.1016/j.xcrm.2022.100561.; Chen G., Shi J.-X., Qi M. et al. Effects of progesterone on intestinal inflammatory response, mucosa structure alterations, and apoptosis following traumatic brain injury in male rats. J Surg Res. 2008;147(1):92–8. https://doi.org/10.1016/j.jss.2007.05.029.; Nalli A.D., Kumar D.P., Mahavadi S. et al. Hypercontractility of intestinal longitudinal smooth muscle induced by cytokines is mediated by the nuclear factor-κB/AMP-activated kinase/myosin light chain kinase pathway. J Pharmacol Exp Therap. 2014;350(1):89–98. https://doi.org/10.1124/jpet.113.212522.; Pang Y., Dong J., Thomas P. Progesterone increases nitric oxide synthesis in human vascular endothelial cells through activation of membrane progesterone receptor-α. Am J Physiol Endocrinol Metab. 2015;308(10):E899–E911. https://doi.org/10.1152/ajpendo.00527.2014.; Andriole G.L., Humphrey P., Ray P. et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol. 2004;172(3):915–9. https://doi.org/10.1097/01.ju.0000136430.37245.b9.; Clark R.V., Hermann D.J., Cunningham G.R. et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89(5):2179–84. https://doi.org/10.1210/jc.2003-030330.; McConnell J.D., Wilson J.D., George F.W. et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1992;74(3):505–8. https://doi.org/10.1210/jcem.74.3.1371291.; Span P.N., Voller M.C., Smals A.G. et al Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. J Urol. 1999;161(1):332–7.; Wu Y., Godoy A., Azzouni F. et al. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors. Prostate. 2013;73(13):1470–82. https://doi.org/10.1002/pros.22694.; Lazier C.B., Thomas L.N., Douglas R.C. et al. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate. 2004;58(2):130–44. https://doi.org/10.1002/pros.10340.; Wu Y., Chhipa R.R., Zhang H., Ip C. The antiandrogenic effect of finasteride against a mutant androgen receptor. Cancer Biol Ther. 2011;11(10):902–9. https://doi.org/10.4161/cbt.11.10.15187.; https://www.gynecology.su/jour/article/view/2529
-
3Academic Journal
Θεματικοί όροι: пептидно-цитокиновый комплекс «Суперлимф 25 ЕД», benign prostatic hyperplasia, prostatitis, пациенты, peptide-cytokine complex 'Superlymph 25 U', иммуномодулятор, immunomodulator, доброкачественная гиперплазия предстательной железы, простатит, patients, older age group, старшая возрастная группа
-
4Academic Journal
Συγγραφείς: Kussainov, A.M., Salmenbaeva, A.B., Musulmanbek, M.E., Bulegenov, T.A., Omarov, N.B., Akimzhanov, K.D., Kuderbayev, M.Т., Kolyado, V.B.
Πηγή: Наука и здравоохранение. :127-132
Θεματικοί όροι: benign prostatic hyperplasia, өлім-жітім, смертность, эпидемиология, epidemiology, доброкачественная гиперплазия предстательной железы, Қазақстан, Казахстан, mortality, қуық асты безінің қатерсіз гиперплазиясы, Kazakhstan, 3. Good health
-
5Academic Journal
Συγγραφείς: Kussainov, A.M., Shalgumbayeva, G.M., Bulegenov, T.A., Salmenbaeva, A.B., Musulmanbek, M.E.
Πηγή: Наука и здравоохранение. :121-27
Θεματικοί όροι: хирургиялық емдеу, surgical treatment, Benign prostatic hyperplasia (BPH), outcome, исход, оперативное лечение, нәтиже, Қазақстан, Казахстан, Қуықасты безінің қатерсіз гиперплазиясы (ҚБҚГ), Kazakhstan, 3. Good health, Доброкачественная гиперплазия предстательной железы (ДГПЖ)
-
6Academic Journal
Συγγραφείς: Kairambayev, Ye.М., Bulegenov, T.А., Akimzhanov, K.D., Kuderbayev, M.Т., Neimark, A.I., Smail, Ye.M., Yurkovskaya, O.A., Zhumanbayeva, Zh.М., Glushkova, N.E.
Πηγή: Наука и здравоохранение. :105-110
Θεματικοί όροι: surgery, benign prostatic hyperplasia, эректильная функция, эректильді функция, оперативное вмешательство, 5-фторурацил, 5-fluorouracil, erectile function, доброкачественная гиперплазия предстательной железы, хирургия, қуық асты безінің қатерсіз гиперплазиясы, 3. Good health
-
7Conference
Θεματικοί όροι: ЛИКОПИН, ДОБРОКАЧЕСТВЕННАЯ ГИПЕРПЛАЗИЯ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ, МОЛОЧНЫЙ ЙОДИРОВАННЫЙ БЕЛОК
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://elar.urfu.ru/handle/10995/135201
-
8Academic Journal
Συγγραφείς: Kairambayev, Ye.М., Bulegenov, T.A., Kuderbayev, M.T., Zhussupov, S.M., Messova, A.M., Yurkovskaya, O.А., Yurkovsky, A.
Πηγή: Наука и здравоохранение. :188-198
Θεματικοί όροι: benign prostatic hyperplasia, стриктуры уретры, емі, treatment, risk factors, факторы риска, доброкачественная гиперплазия предстательной железы, лечение, urethral strictures, Қуық асты безінін катерсіз гиперплазиясы, уретра стриктурасы, кауіп қатер факторы, 3. Good health
-
9Academic Journal
Συγγραφείς: M. I. Katibov, A. B. Bogdanov, M. M. Alibekov, Z. M. Magomedov, O. B. Loran, М. И. Катибов, А. Б. Богданов, М. М. Алибеков, З. М. Магомедов, О. Б. Лоран
Πηγή: Urology Herald; Том 12, № 1 (2024); 27-35 ; Вестник урологии; Том 12, № 1 (2024); 27-35 ; 2308-6424 ; 10.21886/2308-6424-2024-12-1
Θεματικοί όροι: тулиевый лазер, benign prostatic hyperplasia, transurethral resection, laser enucleation, thulium laser, доброкачественная гиперплазия предстательной железы, трансуретральная резекция, лазерная энуклеация
Περιγραφή αρχείου: application/pdf
Relation: https://www.urovest.ru/jour/article/view/827/531; Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36(4):403-415, v. DOI:10.1016/j.ucl.2009.07.003; Malaeb BS, Yu X, McBean AM, Elliott SP. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000-2008). Urology. 2012;79(5):1111-1116. DOI:10.1016/j.urology.2011.11.084; Naspro R, Bachmann A, Gilling P, Kuntz R, Madersbacher S, Montorsi F, Reich O, Stief C, Vavassori I. A review of the recent evidence (2006-2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate. Eur Urol. 2009;55(6):1345-1357. DOI:10.1016/j.eururo.2009.03.070; Patel A, Nunez R, Mmeje CO, Humphreys MR. Safety and feasibility of concomitant surgery during holmium laser enucleation of the prostate (HoLEP). World J Urol. 2014;32(6):1543-1549. DOI:10.1007/s00345-014-1254-0; Myers JB, McAninch JW. Perineal urethrostomy. BJU Int. 2011;107(5):856-865. DOI:10.1111/j.1464-410X.2011.10139.x; Bracka A. A versatile two-stage hypospadias repair. Br J Plast Surg. 1995;48(6):345-352. DOI:10.1016/s0007-1226(95)90023-3; Chong T, Li YQ, Wang ZM, Shi T, Zhang P. [Simultaneous treatment for benign prostate hyperplasia and its concomitant diseases]. Zhonghua Nan Ke Xue. 2006;12(6):534-536. (In Chinese) PMID: 16833196; Коган М.И., Митусов В.В., Красулин В.В., Шангичев А.В., Глухов В.П., Аметов Р.Э., Митусова Е.В. Внутренняя оптическая уретротомия при стриктурной болезни уретры усложняет последующую реконструктивную операцию. Урология. 2012;(3):27-30. eLIBRARY ID: 18065089; EDN: PFIHBD; Коган М.И. Комментарии к новым поправкам (2023) в рекомендации Американской урологической ассоциации по стриктурной болезни уретры. Вестник урологии. 2023;11(3):5-9. DOI:10.21886/2308-6424-2023-11-3-5-9; Wessells H, Morey A, Souter L, Rahimi L, Vanni A. Urethral Stricture Disease Guideline Amendment (2023). J Urol.2023;210(1):64-71. DOI:10.1097/JU.0000000000003482; Катибов М.И., Богданов А.Б. Перинеальная уретростомия: результаты, клинико-статистические и терминологические аспекты. Урология. 2022;(2):113-120. DOI:10.18565/urology.2022.2.113-120; Глухов В.П., Ильяш А.В., Митусов В.В., Сизякин Д.В., Коган М.И. Роль перинеальной уретростомии в лечении пациентов со стриктурами спонгиозной уретры. Вестник урологии. 2022;10(2):87-98. DOI:10.21886/2308-6424-2022-10-2-87-98; Verla W, Oosterlinck W, Waterloos M, Spinoit AF, Lumen N. Perineal Urethrostomy for Complicated Anterior Urethral Strictures: Indications and Patient's Choice. An Analysis at a Single Institution. Urology. 2020;138:160-165. DOI:10.1016/j.urology.2019.11.064; Arya MC, Singhal A, Vasudeo V, Shyoran Y, Gandhi A, Maan R, Sonwal M. Perineal urethrostomy: A single-stage viable option for complex anterior urethral strictures. Urol Ann. 2021;13(2):142-149. DOI:10.4103/UA.UA_111_20; Yadav P, Danish N, Sureka SS, Rustagi S, Kapoor R, Srivastava A, Singh UP. Permanent perineal urethrostomy for anterior urethral strictures: A critical appraisal of long-term outcomes and erectile function. Turk J Urol. 2021;47(2):158-163. DOI:10.5152/tud.2020.20322; Abedi A, Razzaghi MR, Rahavian A, Hazrati E, Aliakbari F, Vahedisoraki V, Allameh F. Is Holmium Laser Enucleation of the Prostate a Good Surgical Alternative in Benign Prostatic Hyperplasia Management? A Review Article. J Lasers Med Sci. 2020;11(2):197-203. DOI:10.34172/jlms.2020.33; Yilmaz M, Esser J, Suarez-Ibarrola R, Gratzke C, Miernik A. Safety and Efficacy of Laser Enucleation of the Prostate in Elderly Patients – A Narrative Review. Clin Interv Aging. 2022;17:15-33. DOI:10.2147/CIA.S347698; Hartung FO, Kowalewski KF, von Hardenberg J, Worst TS, Kriegmair MC, Nuhn P, Herrmann TRW, Michel MS, Herrmann J. Holmium Versus Thulium Laser Enucleation of the Prostate: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol Focus. 2022;8(2):545-554. DOI:10.1016/j.euf.2021.03.024; https://www.urovest.ru/jour/article/view/827
-
10Academic Journal
Συγγραφείς: A. I. Volnukhin, D. Yu. Pushkar, V. A. Malkhasyan, А. И. Волнухин, Д. Ю. Пушкарь, В. А. Малхасян
Πηγή: Urology Herald; Том 12, № 4 (2024); 23-33 ; Вестник урологии; Том 12, № 4 (2024); 23-33 ; 2308-6424 ; 10.21886/2308-6424-2024-12-4
Θεματικοί όροι: интермиттирующая катетеризация, benign prostatic hyperplasia, bladder drainage, intermittent catheterization, доброкачественная гиперплазия предстательной железы, дренирование мочевого пузыря
Περιγραφή αρχείου: application/pdf
Relation: https://www.urovest.ru/jour/article/view/917/585; Desgrandchamps F, De La Taille A, Doublet JD; RetenFrance Study Group. The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia. BJU Int. 2006;97(4):727-733. DOI:10.1111/j.1464-410X.2006.06109.x; Fitzpatrick JM, Desgrandchamps F, Adjali K, Gomez Guerra L, Hong SJ, El Khalid S, Ratana-Olarn K; Reten-World Study Group. Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia. BJU Int. 2012;109(1):88-95. DOI:10.1111/j.1464-410X.2011.10430.x; Малхасян В.А., Котов С.В., Мамаев И.Э., Беломытцев С.В., Перов Р.А., Пульбере С.А., Волнухин А.И., Пушкарь Д.Ю. Эффективность и безопасность интермиттирующей катетеризации для купирования острой задержки мочи: проспективное сравнительное рандомизированное исследование. Урология. 2022;(6):9-15. DOI:10.18565/urology.2022.6.9-15; Пушкарь Д.Ю., Малхасян В.А., Ходырева Л.А., Раснер П.И., Куприянов Ю.А., Дударева А.А., Семенякин И.В., Енгай В.А., Зингеренко М.Б., Зинухов А.Ф., Мамаев И.Э., Ответчиков И.Н., Редькович В.И., Сулейманов С.И., Тахирзаде Т.Б., Тедеев В.В., Трушкин Р.Н., Цыганов С.В., Мотин П.И., Ласский И.А. Анализ и оптимизация медицинской помощи пациентам с острой задержкой мочеиспускания, поступающим в стационары г. Москвы. Экспериментальная и клиническая урология. 2016;(2):4-7. eLIBRARY ID: 29899533; EDN: ZEHOUJ; Зимичев А.А., Виноградов Д.С., Тарасов И.В., Гусев Д.О., Почивалов А.С., Мирзоев Д.Д. Современное состояние проблемы выбора метода деривации мочи у пациентов с острой задержкой мочеиспускания. Аспирантский вестник Поволжья. 2020;20(5-6):143-150. DOI:10.17816/2072-2354.2020.20.3.143-150; Delivering quality health services: a global imperative for universal health coverage. Geneva: World Health Organization, Organisation for Economic Co-operation and Development, and The World Bank; 2018.; Yılmaz B, Akkoç Y, Alaca R, Erhan B, Gündüz B, Yıldız N, Gök H, Köklü K, Cınar E, Alemdaroğlu E, Ersöz M, Karapolat H, Demir Y, Bardak AN, Turna I, Catalbaş N, Güneş S, Tunç H. Intermittent catheterization in patients with traumatic spinal cord injury: obstacles, worries, level of satisfaction. Spinal Cord. 2014;52(11):826-830. DOI:10.1038/sc.2014.134; Hakvoort RA, Nieuwkerk PT, Burger MP, Emanuel MH, Roovers JP. Patient preferences for clean intermittent catheterisation and transurethral indwelling catheterisation for treatment of abnormal postvoid residual bladder volume after vaginal prolapse surgery. BJOG. 2011;118(11):1324-1328. DOI:10.1111/j.1471-0528.2011.03056.x; Abidfaheem T, Lee K. Comparison of health related quality of life and health related outcomes among male patients with spinal cord injury with indwelling vs intermittent bladder catheterization - A pilot study. International Journal of Research in Pharmaceutical Sciences. 2020;11:2537-2542. DOI:10.26452/ijrps.v11iSPL4.4150; Chapple A, Prinjha S, Salisbury H. How users of indwelling urinary catheters talk about sex and sexuality: a qualitative study. Br J Gen Pract. 2014;64(623):e364-e371. DOI:10.3399/bjgp14X680149; Amarenco G, Guinet A, Jousse M, Verollet D, Ismael SS. Pencil and paper test: a new tool to predict the ability of neurological patients to practice clean intermittent self-catheterization. J Urol. 2011;185(2):578-582. DOI:10.1016/j.juro.2010.09.106; Малхасян В.А., Геворкян Р.Р., Семенякин И.В., Пушкарь Д.Ю. Оптимальный метод дренирования мочевого пузыря у пациентов с острой задержкой мочеиспускания. Вопросы урологии и андрологии. 2017;5(2):17-21. DOI:10.20953/2307-6631-2017-2-17-21; Mitsui T, Minami K, Furuno T, Morita H, Koyanagi T. Is suprapubic cystostomy an optimal urinary management in high quadriplegics?. A comparative study of suprapubic cystostomy and clean intermittent catheterization. Eur Urol. 2000;38(4):434-438. DOI:10.1159/000020320; James R, Frasure HE, Mahajan ST. Urinary catheterization may not adversely impact quality of life in multiple sclerosis patients. ISRN Neurol. 2014;2014:167030. DOI:10.1155/2014/167030; Culha Y, Acaroglu R. The Effect of Video-Assisted Clean Intermittent Catheterization Training on Patients' Practical Skills and Self-Confidence. Int Neurourol J. 2022;26(4):331-341. DOI:10.5213/inj.2244166.083; Girotti ME, MacCornick S, Perissé H, Batezini NS, Almeida FG. Determining the variables associated to clean intermittent self-catheterization adherence rate: one-year follow-up study. Int Braz J Urol. 2011;37(6):766-772. DOI:10.1590/s1677-55382011000600013; Parsons BA, Narshi A, Drake MJ. Success rates for learning intermittent self-catheterisation according to age and gender. Int Urol Nephrol. 2012;44(4):1127-1131. DOI:10.1007/s11255-012-0136-x; https://www.urovest.ru/jour/article/view/917
-
11Academic Journal
Συγγραφείς: Sh. A. Abbosov, A. B. Shomarufov, D. R. Aminova, Ш. А. Аббосов, А. Б. Шомаруфов, Д. Р. Аминова
Πηγή: Urology Herald; Том 12, № 4 (2024); 5-13 ; Вестник урологии; Том 12, № 4 (2024); 5-13 ; 2308-6424 ; 10.21886/2308-6424-2024-12-4
Θεματικοί όροι: контрактура шейки мочевого пузыря, benign prostatic hyperplasia, balloon dilation, transrectal ultrasound, доброкачественная гиперплазия предстательной железы, баллонная дилатация
Περιγραφή αρχείου: application/pdf
Relation: https://www.urovest.ru/jour/article/view/907/574; Xiang P, Guan D, Du Z, Hao Y, Yan W, Wang Y, Liu Y, Liu D, Ping H. Efficacy and safety of prostatic artery embolization for benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials. Eur Radiol. 2021;31(7):4929-4946. DOI:10.1007/s00330-020-07663-2; Frendl DM, Chen YW, Chang DC, Kim MM. A Claims Based Assessment of Reoperation and Acute Urinary Retention after Ambulatory Transurethral Surgery for Benign Prostatic Hyperplasia. J Urol. 2021;205(2):532-538. DOI:10.1097/JU.0000000000001390; Arcaniolo D, Manfredi C, Veccia A, Herrmann TRW, Lima E, Mirone V, Fusco F, Fiori C, Antonelli A, Rassweiler J, Liatsikos E, Porpiglia F, De Sio M, Autorino R; EAU Section of Uro-Technology (ESUT) Research Group. Bipolar endoscopic enucleation versus bipolar transurethral resection of the prostate: an ESUT systematic review and cumulative analysis. World J Urol. 2020;38(5):1177-1186. DOI:10.1007/s00345-019-02890-9; Sun F, Sun X, Shi Q, Zhai Y. Transurethral procedures in the treatment of benign prostatic hyperplasia: A systematic review and meta-analysis of effectiveness and complications. Medicine (Baltimore). 2018;97(51):e13360. DOI:10.1097/MD.0000000000013360; Zhang Y, Fu C, Wang J, Wu P, Chen X, Hou H, Song X, Cheng W, Wang J, Liu M. Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser. J Vis Exp. 2020;(159). DOI:10.3791/60532; Enikeev D, Rapoport L, Gazimiev M, Allenov S, Inoyatov J, Taratkin M, Laukhtina E, Sung JM, Okhunov Z, Glybochko P. Monopolar enucleation versus transurethral resection of the prostate for small- and mediumsized (< 80 cc) benign prostate hyperplasia: a prospective analysis. World J Urol. 2020;38(1):167-173. DOI:10.1007/s00345-019-02757-z; Reale G, Marchioni M, Altieri V, Greco F, De Nunzio C, Destefanis P, Ricciardulli S, Bergamaschi F, Fasolis G, Varvello F, Voce S, Palmieri F, Divan C, Malossini G, Oriti R, Tuccio A, Ruggera L, Tubaro A, Delicato G, Laganà A, Dadone C, De Rienzo G, Ditonno A, Frattini A, Pucci L, Carrino M, Montefiore F, Germani S, Miano R, Schips L, Rabito S, Ferrari G, Cindolo L. Operative profile, safety and functional outcomes after GreenLight laser prostate surgery: results from a 12 months follow-up multicenter Italian cohort analyses. Minerva Urol Nefrol. 2020;72(5):622-628. DOI:10.23736/S0393-2249.20.03597-3; Ibrahimi A, Ziani I, El Boukili El Makhoukhi Z, El Sayegh H, Benslimane L, Nouini Y. Transurethral resection syndrome: A rare complication of intraperitoneal bladder perforation during transurethral resection of bladder tumor. Urol Case Rep. 2020;34:101465. DOI:10.1016/j.eucr.2020.101465; Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention. Eur Urol. 2006;50(5):969-979; discussion 980. DOI:10.1016/j.eururo.2005.12.042; Ahyai SA, Gilling P, Kaplan SA, Kuntz RM, Madersbacher S, Montorsi F, Speakman MJ, Stief CG. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol. 2010;58(3):384-397. DOI:10.1016/j.eururo.2010.06.005; Grechenkov A, Sukhanov R, Bezrukov E, Butnaru D, Barbagli G, Vasyutin I, Tivtikyan A, Rapoport L, Alyaev Y, Glybochko P. Risk factors for urethral stricture and/or bladder neck contracture after monopolar transurethral resection of the prostate for benign prostatic hyperplasia. Urologia. 2018;85(4):150-157. DOI:10.1177/0391560318758195; Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, Lack N, Stief CG; Urology Section of the Bavarian Working Group for Quality Assurance. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180(1):246-249. DOI:10.1016/j.juro.2008.03.058; Аббосов Ш.А., Сорокин Н.И., Кадрев А.В., Шомаруфов А.Б., Нестерова О.Ю., Акилов Ф.А., Камалов А.А. Предикторы развития склероза шейки мочевого пузыря после трансуретральных вмешательств на предстательной железе. Урология. 2021;(5):73-77. DOI:10.18565/urology.2021.5.73-77; Barbalias D, Lappas G, Ravazoula P, Liourdi D, Kyriazis I, Liatsikos E, Kallidonis P. Evaluation of the Distribution of Paclitaxel After Application of a Paclitaxel-Coated Balloon in the Rabbit Urethra. J Endourol. 2018;32(5):381-386. DOI:10.1089/end.2017.0935; Рева И.А., Живов А.В., Берников А.Н., Пушкарь Д.Ю. Факторы риска развития и методики коррекции послеоперационного стеноза везикоуретрального анастомоза (обзор литературы). Онкоурология. 2017;13(2):104-112. DOI:10.17650/1726-9776-2017-13-2-104-112; Favre GA, Alfieri AG, Gil Villa SA, Tobia I, Giudice CR. Bulbomembranous Urethral Strictures Repair After Surgical Treatment of Benign Prostatic Hyperplasia. Experience From a Latin American Referral Centre. Urology. 2021;147:281-286. DOI:10.1016/j.urology.2020.08.085; Abbosov SA, Sorokin NI, Shomarufov AB, Kadrev AV, Ugli N, Khusniddin Z, Mukhtarov ST, Akilov FA, Kamalov AA. Bladder Neck Contracture as a Complication of Prostate Surgery. Alternative Treatment Methods and Prospects (Literature Review). Urological Science. 2022;33(2):49-55. DOI:10.4103/UROS.UROS_127_21; Steenkamp JW, Heyns CF, de Kock ML. Internal urethrotomy versus dilation as treatment for male urethral strictures: a prospective, randomized comparison. J Urol. 1997;157(1):98-101. PMID: 8976225.; Vicente J, Salvador J, Caffaratti J. Endoscopic urethrotomy versus urethrotomy plus Nd-YAG laser in the treatment of urethral stricture. Eur Urol. 1990;18(3):166-168. DOI:10.1159/000463901; Lee YH, Chiu AW, Huang JK. Comprehensive study of bladder neck contracture after transurethral resection of prostate. Urology. 2005;65(3):498-503; discussion 503. DOI:10.1016/j.urology.2004.10.082; Мухтаров Ш.Т., Насиров Ф.Р., Бахадирханов М.М., Уралова Н.Д., Акилов Ф.А., Мирхамидов Д.Х., Шомаруфов А.Б., Аббосов Ш.А., Касимов С.С. Оценка эффективности и безопасности эндоскопического лечения облитерации бульбарно-мембранозного отдела уретры. Вестник урологии. 2022;10(4):79-87. DOI:10.21886/2308-6424-2022-10-4-79-87; Abbosov ShA, Sorokin NI, Shomarufov AB, Kadrev AV, Mikheev KV, Fozilov AA, Nadjimitdinov YS, Ohobotov DA, Giyasov ShI, Mukhtarov ShT, Akilov FA, Kamalov AA. Assessment of the Balloon Dilation Efficiency in Bladder Neck Contracture after Transurethral Interventions on the Prostate. Urological Science. 2022;33(3):130-135. DOI:10.4103/UROS.UROS_148_21; Ramchandani P, Banner MP, Berlin JW, Dannenbaum MS, Wein AJ. Vesicourethral anastomotic strictures after radical prostatectomy: efficacy of transurethral balloon dilation. Radiology. 1994;193(2):345-349. DOI:10.1148/radiology.193.2.7972741; Ishii G, Naruoka T, Kasai K, Hata K, Omono H, Suzuki M, Kimura T, Egawa S. High pressure balloon dilation for vesicourethral anastomotic strictures after radical prostatectomy. BMC Urol. 2015;15:62. DOI:10.1186/s12894-015-0059-9; Аббосов Ш.А., Охоботов Д.А., Сорокин Н.И., Шомаруфов А.Б., Шапаров Б.М., Наджимитдинов Я.С., Мухтаров Ш.Т., Акилов Ф.А., Камалов А.А. Оценка эффективности баллонной дилатации рубцового сужения шейки мочевого пузыря после трансуретральных вмешательств на предстательной железе (предварительные результаты). Вестник урологии. 2021;9(1):5-13. DOI:10.21886/2308-6424-2021-9-1-5-13; Vyas JB, Ganpule AP, Muthu V, Sabnis RB, Desai MR. Balloon dilatation for male urethral strictures “revisited”. Urol Ann. 2013;5(4):245-248. DOI:10.4103/0974-7796.120296; Xie TP, Huang XB, Xu QQ, Ye HY, Yang QY, Wang XF. [Balloon dilation by B ultrasound monitoring for treatment of urethral stricture: 5 case reports]. Beijing Da Xue Xue Bao Yi Xue Ban. 2014;46(4):657-658. (In Chinese). PMID: 25131490.; https://www.urovest.ru/jour/article/view/907
-
12Academic Journal
Συγγραφείς: Suslov, A.S.
Πηγή: МЕДИЦИНА НЕВІДКЛАДНИХ СТАНІВ; Том 16, № 4 (2020); 110-114
МЕДИЦИНА НЕОТЛОЖНЫХ СОСТОЯНИЙ; Том 16, № 4 (2020); 110-114
EMERGENCY MEDICINE; Том 16, № 4 (2020); 110-114Θεματικοί όροι: benign prostatic hyperplasia, surgery, transvesical prostatectomy, analgesia, epidural analgesia, 03 medical and health sciences, 0302 clinical medicine, доброякісна гіперплазія передміхурової залози, хірургія, черезміхурова простатектомія, аналгезія, епідуральна аналгезія, доброкачественная гиперплазия предстательной железы, хирургия, чреспузырная простатэктомия, анальгезия, эпидуральная анальгезия, 3. Good health
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://emergency.zaslavsky.com.ua/article/view/207939
-
13Academic Journal
Πηγή: Хирургия. Восточная Европа. :357-366
Θεματικοί όροι: 03 medical and health sciences, benign prostatic hyperplasia, insulin, 0302 clinical medicine, лептин, аполипопротеины, инсулин, доброкачественная гиперплазия предстательной железы, leptin, apolipoproteins, metabolic syndrome, 3. Good health, метаболический синдром
-
14Academic Journal
Συγγραφείς: Volkov, S. N., Mikheev, R. K., Grigoryan, O. R., Tereshchenko, V. I., Stepanchenko, V. S., Andreeva, E. N., Волков, С. Н., Михеев, Р. К., Григорян, О. Р., Терещенко, В. И., Степанченко, В. С., Андреева, Е. Н.
Θεματικοί όροι: BENIGN PROSTATIC HYPERPLASIA, BODY MASS INDEX, COMPARATIVE ANALYSIS, UROLOGY, SURGERY, ДОБРОКАЧЕСТВЕННАЯ ГИПЕРПЛАЗИЯ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ, ИНДЕКС МАССЫ ТЕЛА, КОРРЕЛЯЦИОННЫЙ АНАЛИЗ, УРОЛОГИЯ, ХИРУРГИЯ
Περιγραφή αρχείου: application/pdf
Relation: Уральский медицинский журнал. 2023. Т. 22, № 3.; http://elib.usma.ru/handle/usma/14605
Διαθεσιμότητα: http://elib.usma.ru/handle/usma/14605
-
15Academic Journal
Συγγραφείς: S. V. Popov, R. G. Huseynov, D. A. Saydulaev, S. V. Sadovnikov, Yu. V. Kisil, K. V. Sivak, N. S. Bunenkov, V. V. Perepelitsa, A. S. Ulitina, T. A. Lelyavina, С. В. Попов, Р. Г. Гусейнов, Д. А. Сайдулаев, С. В. Садовников, Ю. В. Кисиль, К. В. Сивак, Н. С. Буненков, В. В. Перепелица, А. С. Улитина, Т. А. Лелявина
Πηγή: Russian Journal of Transplantology and Artificial Organs; Том 25, № 2 (2023); 15-25 ; Вестник трансплантологии и искусственных органов; Том 25, № 2 (2023); 15-25 ; 1995-1191
Θεματικοί όροι: трансплантация почки, benign prostatic hyperplasia, kidney transplantation, доброкачественная гиперплазия предстательной железы
Περιγραφή αρχείου: application/pdf
Relation: https://journal.transpl.ru/vtio/article/view/1603/1467; https://journal.transpl.ru/vtio/article/view/1603/1486; https://journal.transpl.ru/vtio/article/downloadSuppFile/1603/1265; Годовой отчет о трансплантологии в Европе за 2019 год. https://www.eurotransplant.org/wp-content/uploads/2020/06/AnnualReport-2019.pdf.; Готье СВ, Хомяков СМ. Донорство и трансплантация органов в Российской Федерации в 2018 году. XII сообщение Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2019; 21 (3): 7–32. https://doi.org/10.15825/1995-1191-2019.; Кабанова СА, Богопольский ПМ. Пересадка почки: история, итоги и перспективы. Трансплантология. 2015; (2): 49–58.; Султанов ПК, Хаджибаев ФА, Эргашев ДН, Исматов АА. Анализ осложнений после трансплантации почки. Вестник экстренной медицины. 2021; 14 (1): 55–63.; Dos Santos Mantovani M, Coelho de Carvalho N, Archangelo TE, Modelli de Andrade LG, Pires Ferreira Filho S, de Souza Cavalcante R et al. Frailty predicts surgical complications after kidney transplantation. A propensity score matched study. PLoS One. 2020 Feb 26; 15 (2): e0229531.; Bessede T, Hammoudi Y, Bedretdinova D, Parier B, Francois H, Durrbach A, Benoit G. Preoperative Risk Factors Associated With Urinary Complications After Kidney Transplantation. Transplant Proc. 2017 Nov; 49 (9): 2018–2024.; Hickman LA, Sawinski D, Guzzo T, Locke JE. Urologic malignancies in kidney transplantation. Am J Transplant. 2018 Jan; 18 (1): 13–22.; Shimizu T, Sugihara T, Kamei J, Takeshima S, Kinoshita Y, Kubo T et al. Predictive factors and management of urinary tract infections after kidney transplantation: a retrospective cohort study. Clin Exp Nephrol. 2021 Feb; 25 (2): 200–206.; Thuret R, Timsit MO, Kleinclauss F. Chronic kidney disease and kidney transplantation. Prog Urol. 2016 Nov; 26 (15): 882–908.; Billis A, Freitas LLL, Costa LBE, Barreto IS, Botega AAR, Pereira TA, D’Ancona CA. Lower Urinary Tract Symptoms Due to Xanthoma of the Prostate After Kidney Transplantation: A Case Report. Transplant Proc. 2020 Nov; 52 (9): 2736–2738.; Frascà GM, Brigante F, Volpe A, Cosmai L, Gallieni M, Porta C. Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelines. J Nephrol. 2019 Feb; 32 (1): 57–64.; Tan JHS, Bhatia K, Sharma V, Swamy M, van Dellen D, Dhanda R, Khambalia H. Enhanced recovery after surgery recommendations for renal transplantation: guidelines. Br J Surg. 2022 Dec 13; 110 (1): 57–59.; Thuret R, Kleinclauss F, Terrier N, Karam G, Timsit MO. Challenges in renal transplantation. Prog Urol. 2016 Nov; 26 (15): 1001–1044. 14. Maggiore U, Abramowicz D, Budde K. Renal transplantation in the elderly. Transplant Rev (Orlando). 2015 Oct; 29 (4): 191–192.; Rodríguez Faba O, Boissier R, Budde K, Figueiredo A, Taylor CF, Hevia V et al. European Association of Urology Guidelines on Renal Transplantation: Update 2018. Eur Urol Focus. 2018 Mar; 4 (2): 208–215.; Cheung CY, Tang SCW. An update on cancer after kidney transplantation. Nephrol Dial Transplant. 2019 Jun 1; 34 (6): 914–920.; Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tractsymptoms: prevalence and incident rates. Urol Clin North Am. 2016; 43: 289.; De Oliveira Marinho AC, TavaresdaSilva E, Bastos CA, Roseiro A, Parada B, Retroz E et al. Acute Urinary Retention After Kidney Transplant: Effect on Graft Function, Predictive Factors, and Treatment. Transplant Proc. 2021 Jul-Aug; 53 (6): 1933–1938.; Sarier M, Yayar O, Yavuz A, Turgut H, Kukul E. Update on the Management of Urological Problems Following Kidney Transplantation. Urol Int. 2021; 105 (7–8): 541–547.; Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I – Initial Work-up and Medical Management. J Urol. 2021 Oct; 206 (4): 806–817.; Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART II – Surgical Evaluation and Treatment. J Urol. 2021 Oct; 206 (4): 818–826.; Касян ГР, Ходырева ЛА, Дударева АА и др. Комбинированное лечение симптомов нижних мочевых путей у мужчин. Медицинский совет. 2016; 5: 84–90.; Seo JH, Han JS, Lee Y, Myong JP, Ha US. Fall risk related to subtype-specific alpha-antagonists for benign prostatic hyperplasia: a nationwide Korean populationbased cohort study. World J Urol. 2022 Dec; 40 (12): 3043–3048.; Пушкарь ДЮ, Раснер ПИ, Харчилава РР. Российские клинические рекомендации с современными данными ведущих российских специалистов. Симптомы нижних мочевыводящих путей и доброкачественная гиперплазия предстательной железы. Урология. 2016; (2, прилож.): 4–19.; Раснер ПИ, Газимиев МА, Гаджиева ЗК и др. Расстройства мочеиспускания у мужчин: методические рекомендации, № 6. М.: АБВ-пресс, 2017; 35.; Павлов ВН, Галимзянов ВЗ, Казихинуров АА, Пушкарев АМ, Загитов АР, Казихинурова АА, Шарипов ИР. Симптомы нижних мочевыводящих путей и доброкачественная гиперплазия предстательной железы: учебное пособие. Уфа: БГМУ, 2018; 86.; Foster HE, Dahm P, Kohler TS et al. Surgical management of lower urinary tract symptom sattributed to benign prostatic hyperplasia: AUA Guideline amendment 2019. J Urol. 2019; 202: 592.; Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective α1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2013; 189 (1 Suppl): S122–S128.; Homma Y, Kawabe K, Tsukamoto T et al. Estimate criteria for diagnosis and severity in benign prostatic hyperplasia. Int J Urol. 1996; 3: 261–266.; Debruyne F, Boyle P, Calais Da Silva F et al. Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients – PERMAL study subset analysis. Eur Urol. 2004; 45: 773–779.; Razek M, Abolyosr A, Mhammed O, Fathi A, Talaat M, Hassan A. Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. World J Urol. 2022. Aug; 40 (8): 2063–2070.; Lukacs B, Grange JC, Comet D. One-year follow-up of 2829 patients with moderate to severe lower urinarytract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice Urology. 2000; 55: 540–546.; Barendrecht MM, Abrams P, Schumacher H, de a Rosette JJ, Michel MC. Do α1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn. 2008; 27: 226–230.; Fusco F, Creta M, De Nunzio C et al. Progressive bladder remodeling due to bladder outlet obstruction: a systematic review of morphological and molecular evidences in humans. BMC Urol. 2018; 18: 15.; Gul ZG, Kaplan SA. BPH: why do patients fail medical therapy? Curr Urol Rep. 2019; 20: 40.; La Vignera S, Aversa A, Cannarella R, Condorelli RA, Duca Y, Russo GI, Calogero AE. Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects. Expert Opin Pharmacother. 2021 Feb; 22 (2): 179–189.; Alcaraz A, CastroDíaz D, Gacci M, Salonia A, Ficarra V, CarballidoRodríguez J et al. Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-toSevere LUTS-BPH Patients: Results of a Paired Matched Clinical Study. On Behalf Of The Qualiprost Study Group. J Clin Med. 2022 Jun 22; 11 (13): 3615.; Bauer SR, Walter LC, Ensrud KE, Suskind AM, Newman JC, Ricke WA et al. Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy. JAMA Netw Open. 2021 Nov 1; 4 (11): e2134427.; Kuzmenko AV, Kuzmenko VV, Gyaurgiev TA. Comparative analysis of the effectiveness of early and delayed initiation of combined DRUG therapy for bph. Urologiia. 2021 May; (2): 27–30.; Gravas S, Cornu JN, Gacci M et al. EAU guidelines on management of non-neurogenic male LUTS. Presented at 2020 EAU Annual Congress, Amsterdam, Arnhem, The Netherlands. Available at http://uroweb.org/guidelines/compilations-of-all-guidelines/.; Anderson BB, Pariser JJ, Helfand BT. Comparison of Patients Undergoing PVP Versus TURP for LUTS/BPH. Curr Urol Rep. 2015 Aug; 16 (8): 55.; Drouin S, Defortescu G, Prudhomme T, Culty T, Verhoest G, Doerfler A et al. Lower urinary tract symptoms and urinary incontinence in renal transplant recipients and candidates: The French guidelines from CTAFU. Prog Urol. 2021 Jan; 31 (1): 45–49.; Checcucci E, Veccia A, De Cillis S, Piramide F, Volpi G, Amparore D et al. New Ultra-minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia: A Systematic Review and Analysis of Comparative Outcomes. Uro-technology and SoMe Working Group of the Young Academic Urologists Working Party of the European Association of Urology and of the Lower Tract and Research Group of the European Section of Uro-technology. Eur Urol Open Sci. 2021 Sep 22; 33: 28–41.; Righetto M, Mancini M, Modonutti D, Calpista A, Beltrami P, Dal Moro F. Patients with renal transplant and moderate-to-severe LUTS benefit from urodynamic evaluation and early transurethral resection of the prostate. World J Urol. 2021 Dec; 39 (12): 4397–4404.; Sarier M, Tekin S, Duman İ, Yuksel Y, Demir M, Alptekinkaya F et al. Results of transurethral resection of the prostate in renal transplant recipients: a single center experience. World J Urol. 2018 Jan; 36 (1): 99–103.; Rassweiler J, Teber D, Kuntz R et al. Complications of transurethral resection of the prostate (TURP) dincidence, management, and prevention. Eur Urol. 2006; 50: 969.; Liu Z, Li YW, Wu WR et al. Long-term clinicale fficacy and safety profile of transurethral resection of prostate versus plasma kinetic resection of the prostate for benign prostatic hyperplasia. Urology. 2017; 103: 198.; Friedl A, Schneeweiss J, Stangl K et al. The adjustable transobturator male system in stress urinary incontinence after transurethral resection of the prostate. Urology. 2017; 109: 184.; Boston Scientific Corporation: Intended use. Rezum Instruction for Use, 10-2019; 5.; Dixon CM, Rijo Cedano E, Mynderse LA et al. Transurethral convective water vapor as atreatment for lower urinary tract symptom-atology due to benign prostatic hyperplasiausing the Rezum(R) system: evaluation of acuteablative capabilities in the human prostate. Res Rep Urol. 2015; 7: 13.; Bouza C, Lopez T, Magro A et al. Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. BMC Urol. 2006; 6: 14.; McVary KT, Rogers T, Mahon J et al. Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia? J Sex Med. 2018; 15: 1728.; National Institute for Health and Care Excellence: Rezum for treating lower urinary tractsymptoms secondary to benign prostatic hyperplasia (24 June 2020). NICE Guideline No. MTG49.; Mynderse LA, Roehrborn CG, Partin AW et al. Results of a 5-year multicenter trial of a new generation cooled high energy transurethral microwave thermal therapy catheter for benign prostatic hyperplasia. J Urol. 2011; 185: 1804.; Gravas S, Cornu JN, Gacci M et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Arnhem, The Netherlands: EAU Guidelines Office. 2020.; McVary KT, Rogers T, Roehrborn CG. Rezum water vapor thermal therapy for lower urinarytract symptoms associated with benign prostatichyperplasia: 4-year results from randomized controlled study. Urology. 2019; 126: 171.; McVary KT, Roehrborn CG. Three-year out-comes of the prospective, randomized controlled Rezum System Study: convective radio frequency thermal therapy for treatment of lower urinarytract symptoms due to benign prostatic hyperplasia. Urology. 2018; 111: 1.; U.S. Food and Drug Administration: Select Up-dates for Guidance for the Non-Clinical and Clinical Investigation of Devices Used for the Treatment of Benign Prostatic Hyperplasia (BPH): Draft Guidance for Industry and Food and Drug Administration Staff (July 14, 2020).; Roehrborn CG, Wilson TH, Black LK. Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial. J Urol. 2012; 187: 1732.; Miller LE, Chughtai B, Dornbier RA et al. Surgical reintervention rate after prostatic urethral lift: systematic review and meta-analysis involving over 2,000 patients. J Urol. 2020; 204: 1019.; Roehrborn CG, Barkin J, Gange SN et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017; 24: 8802.; Zlotta AR, Giannakopoulos X, Maehlum O et al. Longterm evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol. 2003; 44: 89.; Rosario DJ, Phillips JT, Chapple CR. Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when alpha-adrenergic antagonist therapy fails. J Urol. 2007; 177: 1047.; Hill B, Belville W, Bruskewitz R et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol. 2004; 171: 2336.; Gupta N, Rogers T, Holland B et al. Three-year treatment outcomes of water vapor thermal therapy compared to doxazosin, finasteride and combination drug therapy in men with benign prostatic hyperplasia: cohort data from the MTOPS trial. J Urol. 200; 405: 2018.; Malde S, Rajagopalan A, Patel N et al. Potassium-titanyl-phosphate laser photoselective vaporization for benign prostatic hyperplasia: 5-year follow-up from a district general hospital. J Endourol. 2012; 26: 878.; Lee HE, Kim B, Yoon HS, Suh J, Oh SJ. Outcome of Patients With Elevated Prostate-Specific Antigen and Lower Urinary Tract Symptoms Receiving Holmium Laser Enucleation of the Prostate. Int Neurourol J. 2022 Sep; 26 (3): 248–257.; Takeuchi Y, Sawada Y, Watanabe S, NiItsu Y, Sekido N. Age-specific effect of transurethral holmium laser enucleation of the prostate on overactive bladder in men with benign prostatic hyperplasia: An investigation using an overactive bladder symptom score. Low Urin Tract Symptoms. 2022 Dec 11.; Nohara T, Matsuyama S, Shima T, Kawaguchi S, Seto C. Holmium Laser Enucleation of the Prostate With Percutaneous Nephrostomy Into the Transplanted Kidney in Patient With Severe Benign Prostatic Hyperplasia With Vesicoureteral Reflux – A Case Report. Urol Case Rep. 2015 Dec 10; 4: 33–35.; Prudhomme T, Marquette T, Péré M. Benign Prostatic Hyperplasia Endoscopic Surgical Procedures in Kidney Transplant Recipients: A Comparison Between Holmium Laser Enucleation of the Prostate, GreenLight Photoselective Vaporization of the Prostate, and Transurethral Resection of the Prostate. J Endourol. 2020 Feb; 34 (2): 184–191.; Baboudjian M, Fourmarier M, GondranTellier B, Pradere B, Userovici M, Alegorides C, Barry Delongchamps N. Head-to-head comparison of prostatic urethral lift and water vapor thermal therapy for the treatment of symptomatic benign prostatic hyperplasia: a real-life study. Int Urol Nephrol. 2021 Sep; 53 (9): 1757–1763.; Alexander CE, Scullion MM, Omar MI, Yuan Y, Mamoulakis C, N’Dow JM et al. Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction. Cochrane Database Syst Rev. 2019 Dec 3; 12 (12): CD009629.; Mamoulakis C, Ubbink DT, de la Rosette JJ. Bipolar versus monopolar transurethral resection of the prostate: A systematic review and meta-analysis of randomized controlled trials. Eur Urol. 2009; 56: 798–809. doi:10.1016/j.eururo.2009.06.037.; Ahyai SA, Gilling P, Kaplan SA et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol. 2010; 58: 384–397.; Burke N, Whelan JP, Goeree L et al. Systematic review and meta-analysis of transurethral resection of the prostate vs. minimally invasive procedures for the treatment of benign prostatic obstruction. Urology. 2010; 75: 1015–1022.; Omar MI, Lam TBL, Cameron A et al. Systematic review and meta-analysis of the clinical effectiveness of bipolar compared to monopolar transurethral resection of the prostate. BJU Int. 2014; 113: 24–35.; Cornu JN, Ahyai S, Bachmann A et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: An update. Eur Urol. 2015; 67: 1066–1096.; Mamoulakis C, Sofras F, de la Rosette J et al. Bipolar vs. monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction. Cochrane Database Syst Rev. 2014; 1: CD009629.; Taylor BL, Jaffe WI. Electrosurgical transurethral resection of the prostate and transurethral incision of the prostate (monopolar techniques). Can J Urol. 2015 Oct; 22 Suppl 1: 24–29.; Sarıer M, Duman İ, Demir M, Yüksel Y, Emek M, Kukul E. The outcomes of transurethral incision/resection of the prostate (TUIP/TURP) performed early afterrenal transplantation. Turk J Urol. 2018 Mar; 44 (2): 172–177.; Sarier M, Duman I, Kilic S, Yuksel Y, Demir M, Aslan M et al. Comparative Results of Transurethral Incision with Transurethral Resection of The Prostate in Renal Transplant Recipients with Benign Prostate Hyperplasia. Urol J. 2018 Jul 10; 15 (4): 209–213.; Duty BD, Conlin MJ, Fuchs EF, Barry JM. The current role of endourologic management of renal transplantation complications. Adv Urol. 2013; 2013: 246520.; Cardi A, Palleschi G, Patruno G, Tuffu G, D’Amico FE, De Vico A et al. Robot-assisted simple prostatectomy for treatment of large prostatic adenomas: surgical technique and outcomes from a high-volume robotic centre. World J Urol. 2022 Dec 25.; Law YXT, Chen WJK, Shen L, Chua WJ. Is transurethral needle ablation of prostate out of fashion? Outcomes of single session office-based transurethral needle ablation of prostate in patients with symptomatic benign prostatic hyperplasia. Investig Clin Urol. 2019 Sep; 60 (5): 351–358.; Powell T, Rahman S, Staib L, Bhatia S, Ayyagari R. Operator Learning Curve for Prostatic Artery Embolization and Its Impact on Outcomes in 296 Patients. Cardiovasc Intervent Radiol. 2022 Dec 1.; Goyal P, Salem R, Mouli SK. Controversies in Prostate Artery Embolization: Future Best Practice. Semin Intervent Radiol. 2022 Dec 20; 39 (6): 562–570.; GondranTellier B, McManus R, Sichez PC, Akiki A, Gaillet S, Toledano H et al. Efficacy and Safety of Surgery for Benign Prostatic Obstruction in Patients with Preoperative Urinary Catheter. J Endourol. 2021 Jan; 35 (1): 102–108.; Яремин БИ, Харитонов БИ, Миронов АА, Масликова УВ, Александрова ВЭ. Трансплантация почки – поиск оптимальной хирургической техники. Вестник медицинского института «РЕАВИЗ». 2017; (5): 94–104.; Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V et al. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation. 2020 Apr; 104 (4S1 Suppl 1): S11–S103.; Choudhury S, Haldar B, Pal DK. Spectrum of lower urinary tract symptoms after renal transplant among adult non-urologic anuric patients and their management in a tertiary care center. Urologia. 2022 Feb 3: 3915603211048150. doi:10.1177/03915603211048150.; Клинические рекомендации Европейской ассоциации урологов [Электронный ресурс]. М.: Медконгресс, 2019; 1368.; Интегративная урология. Руководство для врачей / Под ред. П.В. Глыбочко, Ю.Г. Аляева. М.: Медфорум, 2014: 128–239, 314–326.; na P, Baboudjian M, Piana A, Girón I et al. New Generation Pulse Modulation in Holmium:YAG Lasers: A Systematic Review of the Literature and Meta-Analysis. J Clin Med. 2022 Jun 4; 11 (11): 3208.; Perri A, Izzo G, Lofaro D, La Vignera S, Brunetti A, Calogero AE, Aversa A. Erectile Dysfunction after Kidney Transplantation. J Clin Med. 2020 Jun 25; 9 (6): 1991.; Kleinclauss F, Thuret R, Murez T, Timsit MO. Urologic malignancies in renal transplant candidates and recipients. Prog Urol. 2016 Nov; 26 (15): 1094–1113.; Данович МГ. Трансплантация почки. Пер. с англ. под ред. Я.Г. Мойсюка. М.: ГЭОТАР Медиа, 2014; 848.; Latchamsetty KC, Mital D, Jensik S. Use of collagen injections for vesicoureteral reflux in transplanted kidney. Transplant Proc. 2003; 35: 1378.; Li Marzi V, Filocamo MT, Dattolo E. The treatment of fistulae and ureteral stenosis after kidney transplantation. Transplant Proc. 2005; 37: 2516.; Mokos I, Kastelan Z, BasićJukić N, Kes P, Pasini J. Transurethral incision/resection of the prostate (TUIP/ TURP) in operative treatment of repeated bladder outlet obstruction early after kidney transplantation. Acta Clin Croat. 2011 Sep; 50 (3): 381–384.; Védrine N, Nsabimbona B, Soares P, Deteix P, Boiteux JP, Guy L. Transurethral resection or incision of the prostate in the immediate postoperative follow-up of renal transplantation. Prog Urol. 2009 Dec; 19 (11): 845–849.; Gratzke C, Pahde A, Dickmann M, Reich O, Seitz M, Jauch K et al. Predictive factors for urinary retention following kidney transplantation in male patients. Scand J Urol Nephrol. 2012 Feb; 46 (1): 44–47.; Gill BC, Ulchaker JC. Costs of managing benign prostatic hyperplasia in the office and operating room. Curr Urol Rep. 2018; 19: 72.; https://journal.transpl.ru/vtio/article/view/1603
-
16Academic Journal
Συγγραφείς: Z. M. Akhokhov, R. S. Ismailov, M. I. Kogan, З. М. Ахохов, Р. С. Исмаилов, М. И. Коган
Πηγή: Urology Herald; Том 11, № 3 (2023); 98-107 ; Вестник урологии; Том 11, № 3 (2023); 98-107 ; 2308-6424 ; 10.21886/2308-6424-2023-11-3
Θεματικοί όροι: обзор литературы, benign prostatic hyperplasia, prostate cancer, lower urinary tract symptoms, prostate specific antigen, molecular biological markers, ribonucleic acid, review, доброкачественная гиперплазия предстательной железы, рак предстательной железы, симптомы нижних мочевых путей, простатический специфический антиген, молекулярно-биологические маркёры, рибонуклеиновая кислота
Περιγραφή αρχείου: application/pdf
Relation: https://www.urovest.ru/jour/article/view/760/498; Li J, Shi Q, Bai Y, Pu C, Tang Y, Yuan H, Wu Y, Wei Q, Han P. Efficacy and safety of muscarinic antagonists as add-on therapy for male lower urinary tract symptoms. Sci Rep. 2014;4:3948. DOI:10.1038/srep03948; Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am. 2016;43(3):289-97. DOI:10.1016/j.ucl.2016.04.001; Аполихин О.И., Сивков А.В., Комарова В.А., Никушина А.А. Болезни предстательной железы в Российской Федерации: статистические данные 2008-2017 гг. Экспериментальная и клиническая урология. 2019;(2):4-13. DOI:10.29188/2222-8543-2019-11-2-4-12.; Zhu C, Wang DQ, Zi H, Huang Q, Gu JM, Li LY, Guo XP, Li F, Fang C, Li XD, Zeng XT. Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019. Mil Med Res. 2021;8(1):64. DOI:10.1186/s40779-021-00359-8; Platz EA, Joshu CE, Mondul AM, Peskoe SB, Willett WC, Giovannucci E. Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men. J Urol. 2012;188(2):496-501. DOI:10.1016/j.juro.2012.03.125; Garg A, Bansal S, Saha S, Kumar A. Study of correlation of urodynamic profile with symptom scoring and ultrasonographic parameters in patients with benign prostatic hyperplasia. J Family Med Prim Care. 2020;9(1):215-220. DOI:10.4103/jfmpc.jfmpc_698_19; Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011;59(5):671-81. DOI:10.1016/j.eururo.2011.01.044; Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-54. DOI:10.1016/0092-8674(93)90529-y; McGuire A, Brown JA, Kerin MJ. Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev. 2015;34(1):145-55. DOI:10.1007/s10555-015-9551-7; Гареев И.Ф., Бейлерли О.А. Циркулирующие микроРНК как биомаркеры: какие перспективы? Профилактическая медицина. 2018;21(6):142‑150. DOI:10.17116/profmed201821061142; Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Processing of primary microRNAs by the Microprocessor complex. Nature. 2004;432(7014):231-5. DOI:10.1038/nature03049; Broughton JP, Lovci MT, Huang JL, Yeo GW, Pasquinelli AE. Pairing beyond the Seed Supports MicroRNA Targeting Specificity. Mol Cell. 2016;64(2):320-333. DOI:10.1016/j.molcel.2016.09.004; de Rie D, Abugessaisa I, Alam T, Arner E, Arner P, Ashoor H, Åström G, Babina M, Bertin N, Burroughs AM, Carlisle AJ, Daub CO, Detmar M, Deviatiiarov R, Fort A, Gebhard C, Goldowitz D, Guhl S, Ha TJ, Harshbarger J, Hasegawa A, Hashimoto K, Herlyn M, Heutink P, Hitchens KJ, Hon CC, Huang E, Ishizu Y, Kai C, Kasukawa T, Klinken P, Lassmann T, Lecellier CH, Lee W, Lizio M, Makeev V, Mathelier A, Medvedeva YA, Mejhert N, Mungall CJ, Noma S, Ohshima M, Okada-Hatakeyama M, Persson H, Rizzu P, Roudnicky F, Sætrom P, Sato H, Severin J, Shin JW, Swoboda RK, Tarui H, Toyoda H, Vitting-Seerup K, Winteringham L, Yamaguchi Y, Yasuzawa K, Yoneda M, Yumoto N, Zabierowski S, Zhang PG, Wells CA, Summers KM, Kawaji H, Sandelin A, Rehli M; FANTOM Consortium; Hayashizaki Y, Carninci P, Forrest ARR, de Hoon MJL. An integrated expression atlas of miRNAs and their promoters in human and mouse. Nat Biotechnol. 2017;35(9):872-878. DOI:10.1038/nbt.3947; Tanzer A, Stadler PF. Molecular evolution of a microRNA cluster. J Mol Biol. 2004;339(2):327-35. DOI:10.1016/j.jmb.2004.03.065; Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet. 2004;5(5):396-400. DOI:10.1038/nrg1328; Fabris L, Ceder Y, Chinnaiyan AM, Jenster GW, Sorensen KD, Tomlins S, Visakorpi T, Calin GA. The Potential of MicroRNAs as Prostate Cancer Biomarkers. Eur Urol. 2016;70(2):312-22. DOI:10.1016/j.eururo.2015.12.054; Greco F, Inferrera A, La Rocca R, Navarra M, Casciaro M, Grosso G, Gangemi S, Ficarra V, Mirone V. The Potential Role of MicroRNAs as Biomarkers in Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. Eur Urol Focus. 2019;5(3):497-507. DOI:10.1016/j.euf.2018.01.008; Sharova E, Grassi A, Marcer A, Ruggero K, Pinto F, Bassi P, Zanovello P, Zattoni F, D'Agostino DM, Iafrate M, Ciminale V. A circulating miRNA assay as a first-line test for prostate cancer screening. Br J Cancer. 2016;114(12):1362-6. DOI:10.1038/bjc.2016.151; Paziewska A, Mikula M, Dabrowska M, Kulecka M, Goryca K, Antoniewicz A, Dobruch J, Borowka A, Rutkowski P, Ostrowski J. Candidate diagnostic miRNAs that can detect cancer in prostate biopsy. Prostate. 2018;78(3):178-185. DOI:10.1002/pros.23427; Al-Kafaji G, Said HM, Alam MA, Al Naieb ZT. Blood-based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer-risk stratification. Oncol Lett. 2018;16(1):1357-1365. DOI:10.3892/ol.2018.8778; Cochetti G, Poli G, Guelfi G, Boni A, Egidi MG, Mearini E. Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role. Onco Targets Ther. 2016;9:7545-7553. DOI:10.2147/OTT.S119027; Dülgeroğlu Y, Eroğlu O. Serum Levels of miR-223-3p and miR-223-5p in Prostate Diseases. Microrna. 2020;9(4):303-309. DOI:10.2174/2211536609666201106090458; Knyazev EN, Fomicheva KA, Mikhailenko DS, Nyushko KM, Samatov TR, Alekseev BY, Shkurnikov MY. Plasma Levels of hsa-miR-619-5p and hsa-miR-1184 Differ in Prostatic Benign Hyperplasia and Cancer. Bull Exp Biol Med. 2016;161(1):108-11. DOI:10.1007/s10517-016-3357-7; Jin W, Fei X, Wang X, Chen F, Song Y. Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia. J Immunol Res. 2020;2020:5873056. DOI:10.1155/2020/5873056; Wang H, Yang L, Mi Y, Wang Y, Ma C, Zhao J, Liu P, Gao Y, Li P. Diagnostic Value of Prostate-Specific Antigen Combined with Plasma miRNA-149 Expression in Patients with Prostate Cancer Based on Experimental Data and Bioinformatics. Contrast Media Mol Imaging. 2022;2022:6094409. DOI:10.1155/2022/6094409; Coradduzza D, Solinas T, Balzano F, Culeddu N, Rossi N, Cruciani S, Azara E, Maioli M, Zinellu A, De Miglio MR, Madonia M, Falchi M, Carru C. miRNAs as Molecular Biomarkers for Prostate Cancer. J Mol Diagn. 2022;24(11):1171-1180. DOI:10.1016/j.jmoldx.2022.05.005; Abramovic I, Vrhovec B, Skara L, Vrtaric A, Nikolac Gabaj N, Kulis T, Stimac G, Ljiljak D, Ruzic B, Kastelan Z, Kruslin B, Bulic-Jakus F, Ulamec M, Katusic-Bojanac A, Sincic N. MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia. Cancers (Basel). 2021;13(9):2068. DOI:10.3390/cancers13092068; Yun SJ, Jeong P, Kang HW, Kim YH, Kim EA, Yan C, Choi YK, Kim D, Kim JM, Kim SK, Kim SY, Kim ST, Kim WT, Lee OJ, Koh GY, Moon SK, Kim IY, Kim J, Choi YH, Kim WJ. Urinary MicroRNAs of Prostate Cancer: Virus-Encoded hsv1-miRH18 and hsv2-miR-H9-5p Could Be Valuable Diagnostic Markers. Int Neurourol J. 2015;19(2):74-84. DOI:10.5213/inj.2015.19.2.74; Kang HW, Byun YJ, Moon SM, Kim K, Piao XM, Zheng CM, Moon SK, Choi YH, Kim WT, Kim YJ, Lee SC, Yun SJ, Kim WJ. Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone. Investig Clin Urol. 2022;63(2):238-244. DOI:10.4111/icu.20210493; Byun YJ, Piao XM, Jeong P, Kang HW, Seo SP, Moon SK, Lee JY, Choi YH, Lee HY, Kim WT, Lee SC, Cha EJ, Yun SJ, Kim WJ. Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer. Investig Clin Urol. 2021;62(3):340-348. DOI:10.4111/icu.20200488; Guzel E, Karatas OF, Semercioz A, Ekici S, Aykan S, Yentur S, Creighton CJ, Ittmann M, Ozen M. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer. Int J Cancer. 2015;136(4):875-9. DOI:10.1002/ijc.29054; Bernardes JGB, Fernandes MR, Rodrigues JCG, Vinagre LWMS, Pastana LF, Dobbin EAF, Medeiros JAG, Dias Junior LB, Bernardes GM, Bernardes IMM, Santos NPCD, Demachki S, Burbano RMR. Association of Androgenic Regulation and MicroRNAs in Acinar Adenocarcinoma of Prostate. Genes (Basel). 2022;13(4):622. DOI:10.3390/genes13040622; Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, McVary KT, Mirone V, Porst H, Roehrborn CG. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011;60(4):809-25. DOI:10.1016/j.eururo.2011.06.037; Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. BJU Int. 2015;115(4):508-19. DOI:10.1111/bju.12745; Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010;42(8):1273-81. DOI:10.1016/j.biocel.2009.12.014; Kim WT, Kim WJ. MicroRNAs in prostate cancer. Prostate Int. 2013;1(1):3-9. DOI:10.12954/PI.12011; Плевако Д.С., Князева М.С., Сидина Е.И., Беркут М.В., Рева С.А., Толмачев С.С., Артемьева А.С., Носов А.К., Малек А.В. Влияние таксанов на экспрессию miR-106 и miR-200с клетками рака предстательной железы in vivo и in vitro. Вестник урологии. 2022;10(4):98-108. DOI:10.21886/2308-6424-2022-10-4-98-108; Старцев В.Ю., Шпоть Е.В., Караев Д.К., Кривоносов Д.И. Выявление рака предстательной железы у мужчин молодого и среднего возрастов. Вестник урологии. 2022;10(1):110-120. DOI:10.21886/2308-6424-2022-10-1-110-120; Song C, Chen H, Wang T, Zhang W, Ru G, Lang J. Expression profile analysis of microRNAs in prostate cancer by next-generation sequencing. Prostate. 2015;75(5):500-16. DOI:10.1002/pros.22936; Fang YX, Gao WQ. Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene. 2014;33(2):135-47. DOI:10.1038/onc.2013.54; Kristensen H, Haldrup C, Strand S, Mundbjerg K, Mortensen MM, Thorsen K, Ostenfeld MS, Wild PJ, Arsov C, Goering W, Visakorpi T, Egevad L, Lindberg J, Grönberg H, Høyer S, Borre M, Ørntoft TF, Sørensen KD. Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clin Cancer Res. 2014;20(8):2169-81. DOI:10.1158/1078-0432.CCR-13-2642; Alcaraz A, Hammerer P, Tubaro A, Schröder FH, Castro R. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol. 2009;55(4):864-73. DOI:10.1016/j.eururo.2008.11.011; https://www.urovest.ru/jour/article/view/760
-
17Academic Journal
Συγγραφείς: Zh. R. Cherkasova, S. A. Tsurkan, A. I. Prostyakova, A. M. Boroda, A. A. Rozhkov, Yu. N. Pirogova, N. M. Nikitina, M. I. Sekacheva, Ж. Р. Черкасова, С. А. Цуркан, А. И. Простякова, А. М. Борода, А. А. Рожков, Ю. Н. Пирогова, Н. М. Никитина, М. И. Секачева
Συνεισφορές: The study was conducted with funding of the Ministry of Science and Higher Education of the Russian Federation within the framework of state support for the creation and development of World‑Class Research Centers «Digital bio design and personalized healthcare» № 075‑15‑2022‑304., Работа выполнена при финансовой поддержке Министерства науки и высшего образования Российской Федерации в рамках государственной поддержки создания и развития научных центров мирового уровня «Цифровой биодизайн и персонализированное здравоохранение» № 075–15–2022–304.
Πηγή: Research and Practical Medicine Journal; Том 10, № 1 (2023); 10-26 ; Research'n Practical Medicine Journal; Том 10, № 1 (2023); 10-26 ; 2410-1893 ; 10.17709/2410-1893-2023-10-1
Θεματικοί όροι: биопсия предстательной железы, prostate cancer, benign prostatic hyperplasia, prostate‑specific antigen, CA‑62 cancer antigen, prostate biopsy, рак предстательной железы, доброкачественная гиперплазия предстательной железы, простат‑специфический антиген, раковый антиген СА‑62
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpmj.ru/rpmj/article/view/874/534; International Agency for Research on Cancer. GLOBOCAN 2020: Cancer incidence and mortality worldwide in 2020. Available at: https://gco.iarc.fr/today/fact-sheets-cancers. Accessed: 10.02.2023.; Злокачественные новообразования в России в 2020 году (заболеваемость и смертность).Под ред. Каприна А.Д., Старинского В. В., Шахзадовой А. О. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. Доступно по: https://glavonco.ru/cancer_register/Забол_2020_Электр.pdf. Дата обращения 10.02.2023.; Каприн А. Д. Алексеев Б. Я., Матвеев В. Б., Пушкарь Д. Ю., Говоров А. В., Горбань Н. А., и др. Рак предстательной железы. Клинические рекомендации. Современная онкология. 2021;23(2):211–247. https://doi.org/10.26442/18151434.2021.2.200959; Руководство по ранней диагностике рака. Всемирная организация здравоохранения, 2018, ISBN 978‑92‑4‑451194‑7. Доступно по: https://apps.who.int/iris/bitstream/handle/10665/272264/9789244511947-rus.pdf. Дата обращения 10.02.2023.; Lundgren PO, Kjellman A, Norming U, Gustafsson O. Long‑Term Outcome of a Single Intervention Population Based Prostate Cancer Screening Study. J Urol. 2018 Jul;200(1):82–88. https://doi.org/10.1016/j.juro.2018.01.080; Misra‑Hebert AD, Hu B, Klein EA, Stephenson A, Taksler GB, Kattan MW, Rothberg MB. Prostate cancer screening practices in a large, integrated health system: 2007‑2014. BJU Int. 2017 Aug;120(2):257–264. https://doi.org/10.1111/bju.13793; Vickers AJ. Prostate Cancer Screening: Time to Question How to Optimize the Ratio of Benefits and Harms. Ann Intern Med. 2017 Oct 3;167(7):509–510. https://doi.org/10.7326/m17‑2012; Jahn JL, Giovannucci EL, Stampfer MJ. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate‑specific Antigen‑era. Int J Cancer. 2015 Dec 15;137(12):2795–2802. https://doi.org/10.1002/ijc.29408; Сергеева Н. С., Скачкова Т. Е., Маршутина Н. В., Алексеев Б. Я., Каприн А. Д. Клиническая значимость ПСА‑ассоциированных тестов в диагностике и стадировании рака предстательной железы. Онкология. Журнал им. П.А. Герцена. 2018;7(1):55–67. https://doi.org/10.17116/onkolog20187155‑67; Verbeek JFM, Bangma CH, Kweldam CF, van der Kwast TH, Kümmerlin IP, van Leenders GJLH, Roobol MJ. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. Urol Oncol. 2019 Feb;37(2):138–144. https://doi.org/10.1016/j.urolonc.2018.11.021; Detsky JS, Ghiam AF, Mamedov A, Commisso K, Commisso A, Zhang L, et al. Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer. J Urol. 2020 Nov;204(5):934–940. https://doi.org/10.1097/ju.0000000000001091; Collins GN, Lloyd SN, Hehir M, McKelvie GB. Multiple transrectal ultrasound‑guided prostatic biopsies‑‑true morbidity and patient acceptance. Br J Urol. 1993 Apr;71(4):460–463. https://doi.org/10.1111/j.1464‑410x.1993.tb15993.x; Демин А. А., Говоров А. В., Васильев А. О. и др. Современный взгляд на биопсию предстательной железы. Consilium Medicum. 2018;20(7):11–14. https://doi.org/10.26442/2075‑1753_2018.7.11‑14; Tcherkassova J, Prostyakova A, Tsurkan S, Ragoulin V, Boroda A, Sekacheva M. Diagnostic efficacy of the new prospective biomarker’s combination CA 15‑3 and CA‑62 for early‑stage breast cancer detection: Results of the blind prospective‑retrospective clinical study. Cancer Biomark. 2022;35(1):57–69. https://doi.org/10.3233/cbm‑210533; Cherkasova JR, Tsurkan SA, Kondratiev VB, Moro‑Vidal R. Cancer antigen for early cancer detection. Patent RU2020114411A, WO2021215955A1 (2021). Available at: https://patents.google.com/patent/WO2021215955A1/en?oq=WO2021215955A1; Патент РФ RU2735918C2 Набор реагентов для выявления маркера эпителиальных карцином.2018.; Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.; Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement. 1960;20:37–46.; Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions. 3rd ed. New York: Wiley; 2003.; Gilchrist JM. Weighted 2 x 2 kappa coefficients: recommended indices of diagnostic accuracy for evidence‑based practice. J Clin Epidemiol. 2009 Oct;62(10):1045–1053. https://doi.org/10.1016/j.jclinepi.2008.11.012; Thomsen FB, Westerberg M, Garmo H, Robinson D, Holmberg L, Ulmert HD, Stattin P. Prediction of metastatic prostate cancer by prostate‑specific antigen in combination with T stage and Gleason Grade: Nationwide, population‑based register study. PLoS One. 2020 Jan 29;15(1):e0228447. https://doi.org/10.1371/journal.pone.0228447; Roddam AW, Rimmer J, Nickerson C, Ward AM; NHS Prostate Cancer Risk Management Programme. Prostate‑specific antigen: bias and molarity of commercial assays for PSA in use in England. Ann Clin Biochem. 2006 Jan;43(Pt 1):35–48. https://doi.org/10.1258/000456306775141731; Scott RJ, Mehta A, Macedo GS, Borisov PS, Kanesvaran R, El Metnawy W. Genetic testing for homologous recombination repair (HRR) in metastatic castration‑resistant prostate cancer (mCRPC): challenges and solutions. Oncotarget. 2021 Aug 3;12(16):1600–1614. https://doi.org/10.18632/oncotarget.28015; Мусаелян А. А., Назаров В. Д., Лапин С. В., Борискин А. Г., Рева С. А., Лебедев Д. Г., и др. Диагностическая значимость PCA3, TMPRSS2:ERG и производных простатического специфического антигена в выявлении рака предстательной железы. Онкоурология. 2020;16(2):65–73. https://doi.org/10.17650/1726‑9776‑2020‑16‑2‑65‑73; Balk SP, Ko YJ, Bubley GJ. Biology of prostate‑specific antigen. J Clin Oncol. 2003 Jan 15;21(2):383–391. https://doi.org/10.1200/jco.2003.02.083; Kimura T, Sato S, Takahashi H, Egawa S. Global Trends of Latent Prostate Cancer in Autopsy Studies. Cancers (Basel). 2021 Jan 19;13(2):359. https://doi.org/10.3390/cancers13020359; Ha H, Chung JW, Ha YS, Choi SH, Lee JN, Kim BS, et al. Clinical significance of the De Ritis ratio for detecting prostate cancer in a repeat prostate biopsy. Investig Clin Urol. 2019 Nov;60(6):447–453. https://doi.org/10.4111/icu.2019.60.6.447; Говоров А. В., Васильев А. О., Ширяев А. А., Бродецкий Б. М., Садченко А. В., Ковылина М. В., и др. Сравнительный анализ результатов биопсии предстательной железы под контролем ТРУЗИ, системы HistoscanningTM и МРТ: выбор оптимальной тактики для выявления рака предстательной железы. Материалы 12‑го международного конгресса Российского общества онкоурологов. М., 2017, с. 20–21. Доступно по: https://www.calameo.com/books/0045207367ad73a665cd2. Дата обращения: 10.02.2023.; Detsky J, Ghiam AF, Mamedov A, Commisso K, Commisso A, Klotz L, et al. Impact of compliance on outcomes for patients on active surveillance for prostate cancer. Journal of Clinical Oncology. 2019;37(7):36–36. DOI:10.1200/JCO.2019.37.7_suppl.36; Аполихин О. И., Сивков А. В., Шишкин С. В., Шейман И. М., Сон И. М., Катибов М. И., и др. Медико‑экономические аспекты комплексной этапной стандартизованной программы диагностики и лечения доброкачественной гиперплазии предстательной железы. Экспериментальная и клиническая урология. 2014;3:4–8.; https://www.rpmj.ru/rpmj/article/view/874
-
18Academic Journal
Συγγραφείς: T. Kh. Nazarov, U. V. Abulboqiev, Т. Х. Назаров, У. В. Абулбокиев
Πηγή: Andrology and Genital Surgery; Том 24, № 1 (2023); 48-56 ; Андрология и генитальная хирургия; Том 24, № 1 (2023); 48-56 ; 2412-8902 ; 2070-9781
Θεματικοί όροι: компьютерная томография, prostate stones, benign prostatic hyperplasia, prostate cancer, prostatitis, lower urinary tract symptoms, transrectal ultrasound examination, computed tomography, камни предстательной железы, доброкачественная гиперплазия предстательной железы, рак предстательной железы, простатит, симптомы со стороны нижних мочевыводящих путей, трансректальное ультразвуковое исследование
Περιγραφή αρχείου: application/pdf
Relation: https://agx.abvpress.ru/jour/article/view/635/502; Fox M. The natural history and significance of stone formation in the prostate gland. J Urol 1963;89(5):716–27. DOI:10.1016/s0022-5347(17)64633-0; Thomas B.A., Robert J.T. Prostatic calculi. J Urol (Baltimore) 1927;18(5):470–93.; Cao J.-J., Huang W., Wu H.-S. et al. Prostatic calculi: do they matter? Sex Med Rev 2018;6(3):482–91. DOI:10.1016/j.sxmr.2017.10.003; Fox M. The association of stones in the upper urinary tract with prostatic calculi. Br J Urol 1960;32(4):458–63. DOI:10.1111/j.1464-410x.1960.tb11570.x; Sоndergaard G., Vetner M., Christensen P.O. Prostatic calculi. Acta Pathol Microbiol Immunol Scand A 1987;95(3):141–5. DOI:10.1111/j.1699-0463.1987.tb00021_95a.x; Geramoutsos I., Gyftopoulos K., Perimenis P. et al. Clinical correlation of prostatic lithiasis with chronic pelvic pain syndromes in young adults. Eur Urol 2004;45(3):333–7; discussion 337–8. DOI:10.1016/j.eururo.2003.09.020; O’Neill A., Lyons C.A., Jain S. et al. EP-2110: A study of prostatic calculi: in patients receiving radical radiotherapy for prostate cancer. Radiother Oncol 2016;119:S992. DOI:10.1016/S0167-8140(16)33361-8; Suh J.H., Gardner J.M., Kee K.H. et al. Calcifications in prostate and ejaculatory system: a study on 298 consecutive whole mount sections of prostate from radical prostatectomy or cystoprostatectomy specimens. Ann Diagn Pathol 2008;12(3):165–70. DOI:10.1016/j.anndiagpath.2007.07.001; Tang Z., Wu X.-M., Wei Q., Wu L.-N. The prevalence and risk factors of prostatic calcification: an analysis of 68 705 subjects. Asian J Androl 2018;20(4):417–9. DOI:10.4103/aja.aja_41_17; Meng J., Zhang M., Guan S.-Y. et al. The prevalence and risk factors of prostatic calculi in Han Chinese: a cross-sectional study based on health examinations. Aging Male 2020;23(5):887–92. DOI:10.1080/13685538.2019.1620203; Klimas R., Bennett B., Gardner W.A. Jr. Prostatic calculi: a review. Prostate 1985;7(1):91–6. DOI:10.1002/pros.2990070110; Мохаммед А.К.Ш. Камни предстательной железы (этиология, клиника, диагностика и лечение). Автореф. дис. … канд. мед. наук. М., 1989. 24 с.; Пасечников С.П., Возианов С.А., Лесовой В.Н. и др. Урология: учебник для студ. высших мед. учебн. заведений. Под ред. С.П. Пасечникова. Пер. с укр. изд. Изд. 2. Винница: Нова Книга, 2015. 456 с.; Hyun J.S. Clinical significance of prostatic calculi: a review. World J Mens Health 2018;36(1):15–21. DOI:10.5534/wjmh.17018; Leader A.J.,Queen D.M. Prostatic calculous disease. J Urol 1958;80(2):142–6. DOI:10.1016/s0022-5347(17)66149-4; Park B., Choo S.H. The burden of prostatic calculi is more important than the presence. Asian J Androl 2017;19(4):482–5. DOI:10.4103/1008-682X.181193; Афанасьев Ю.И., Юрина Н.А., Котовский Е.Ф. и др. Гистология, эмбриология, цитология: учебник. Под ред. Ю.И. Афанасьева, Н.А. Юриной. 6-е изд., перераб. и дополн. М.: ГЭОТАРМедиа, 2012. 800 с.; Lee S.E., Ku J.H., Park H.K. et al. Prostatic calculi do not influence the level of serum prostate specific antigen in men without clinically detectable prostate cancer or prostatitis. J Urol 2003;170(3):745–8. DOI:10.1097/01.ju.0000081650.23715.4c; Струков А.И., Серов В.В. Патологическая анатомия: учебник. 4-е изд., стереотипное. M.: Медицина, 1995. 88 с.; Song W., Zukor H., Liberman A. et al. Astroglial heme oxygenase-1 and the origin of corpora amylacea in aging and degenerating neural tissues. Exp Neurol 2014;254:78–89. DOI:10.1016/j.expneurol.2014.01.006; Eikelenboom P., Veerhuis R., Scheper W. et al. The significance of neuroinflammation in understanding Alzheimer’s disease. J Neural Transm (Vienna) 2006;113(11):1685–95. DOI:10.1007/s00702-006-0575-6; Singhrao S.K., Neal J.W., Newman G.R. Corpora amylacea could be an indicator of neurodegeneration. Neuropathol Appl Neurobiol 1993;19(3):269–76. DOI:10.1111/j.1365-2990.1993.tb00437.x; Chung M.H., Horoupian D.S. Corpora amylacea: a marker for mesial temporal sclerosis. J Neuropathol Exp Neurol 1996;55(4):403–8.; Cissé S., Perry G., Lacoste-Royal G. et al. Immunochemical identification of ubiquitin and heat-shock proteins in corpora amylacea from normal aged and Alzheimer’s disease brains. Acta Neuropathol 1993;85(3):233–40. DOI:10.1007/BF00227716; Hoyaux D., Decaestecker C., Heizmann C.W. et al. S100 proteins in Corpora Amylacea from normal human brain. Brain Res 2000;867(1–2):280–8. DOI:10.1016/s0006-8993(00)02393-3; Botez G., Rami A. Immunoreactivity for Bcl-2 and C-Jun/AP1 in hippocampal corpora amylacea after ischaemia in humans. Neuropathol Appl Neurobiol 2001;27(6):474–80. DOI:10.1046/j.1365-2990.2001.00362.x; Комяков Б.К. Урология: учебник. 2-е изд., перераб. и дополн. М.: ГЭОТАР-Медиа, 2018. 480 с.; Комяков Б.К., Назаров Т.Х., Ризоев Х.Х. Хронический обструктивный простатит: монография. Изд. 2-е, доп. СПб: Русская коллекция, 2016. 111 с.; Назаров Т.Н., Михайличенко В.В. Эффективность применения препарата таденан при хроническом простатите, осложненном бесплодием. Урология 2008;(4):40–3.; Назаров Т.Н., Новиков А.И, Михайличенко В.В., Ризоев Х.Х. и др. Применение димексид-ферментной смеси в комплексной терапии хронического бактериального простатита у мужчин с нарушением фертильности. Андрология и генитальная хирургия 2011;4:54–7.; Bartoletti R., Cai T., Nesi G. et al. The impact of biofilm-producing bacteria on chronic bacterial prostatitis treatment: results from a longitudinal cohort study. World J Urol 2014;32(3):737–42. DOI:10.1007/s00345-013-1145-9; Koseoglu H., Aslan G., Sen B.H. et al. [Prostatic calculi: silent stones (In Spanish)]. Actas Urol Esp 2010;34(6);555–9. DOI:10.1016/S2173-5786(10)70129-3; Dessombz A., Méria P., Bazin D., Daudon M. Prostatic stones: evidence of a specific chemistry related to infection and presence of bacterial imprints. PLoS One 2012;7(12):e51691. DOI:10.1371/journal.pone.0051691; Тиктинский О.Л., Тиктинский Н.О. Инфекционный простатит и эпидемиология. Материалы пленума правления Российского общества урологов. М., 2004. С. 369.; Ткачук В.Н. Хронический простатит. М.: Медицина для всех, 2006. 112 с.; Sutor D.J., Wooley S.E. The crystalline composition of prostatic calculi. Br J Urol 1974;46(5):533–5. DOI:10.1111/j.1464-410x.1974.tb03852.x; Torres Ramirez C., Aguilar Ruiz J., Zuluaga Gomez A. et al. A crystallographic study of prostatic calculi. J Urol 1980;124(6):840–3. DOI:10.1016/s0022-5347(17)55691-8; Cristol D.S., Emmett J.L. The incidence of coincident prostatic calculi, prostatic hyperplasia and carcinoma of the prostate gland. JAMA 1944;124(10):646. DOI:10.1001/jama.1944.62850100004008a; Griffiths G.J., Clements R., Jones D.R. et al. The ultrasound appearances of prostatic cancer with histological correlation. Clin Radiol 1987;38(3):219–27. DOI:10.1016/s0009-9260(87)80048-x; Smolski M., Turo R., Whiteside S. et al. Prevalence of prostatic calcification subtypes and association with prostate cancer. Urology 2015;85(1):178–81. DOI:10.1016/j.urology.2014.09.026; Dell Atti L., Galosi A.B., Ippolito C. Prostatic calculi detected in peripheral zone of the gland during a transrectal ultrasound biopsy can be significant predictors of prostate cancer. Arch Ital Urol Androl 2016;88(4):304–7. DOI:10.4081/aiua.2016.4.304; Kim S.H., Jung K.I., Koh J.S. et al. Lower urinary tract symptoms in benign prostatic hyperplasia patients: orchestrated by chronic prostatic inflammation and prostatic calculi? Urol Int 2013;90(2):144–9. DOI:10.1159/000342643; Harada K., Igari D., Tanahashi Y. Gray scale transrectal ultransonography of the prostate. J Clin Ultrasound 1979;7(1):45–9. DOI:10.1002/jcu.1870070113; Гусейнов Ф.И.О., Камни предстательной железы у больных аденомой и раком простаты. Дис. … канд. мед. наук. М., 2013. 123 с.; Epstein J.I. Prostate biopsy interpretation, 2nd edn. Philadelphia: Lippincott Raven, 1995. 30 p.; Bai Y., Wang M.-Y., Han Y.-H. et al. Susceptibility weighted imaging: a new tool in the diagnosis of prostate cancer and detection of prostatic calcification. PLoS One 2013;8(1):e53237. DOI:10.1371/journal.pone.0053237; Sfanos K.S., Wilson B.A., De Marzo A.M., Isaacs W.B. Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer. Proc Natl Acad Sci U S A 2009;106(9):3443–8. DOI:10.1073/pnas.0810473106; Yanamandra K., Alexeyev O., Zamotin V. et al. Amyloid formation by the pro-inflammatory S100A8/A9 proteins in the ageing prostate. PLoS One 2009;4(5):e5562. DoI:10.1371/journal. pone.0005562; Horita S., Nitta K., Ozasa H. et al. Localization of beta-2-microglobulin in prostatic corpora amylacea of prostatic hypertrophy patients. Nephron 1996;72(4):730–1. DOI:10.1159/000188981; Vilches J., Lopez A., De Palacio L. et al. SEM and X-ray microanalysis of human prostatic calculi. J Urol 1982;127(2):371–3. DOI: 1016/s0022-5347(17)53784-2; Najoui M., Qarro A., Ammani A., Alami M. Giant prostatic calculi. Pan Afr Med J 2013;14:69. DOI:10.11604/pamj.2013.14.69.2376; Kapogiannis F., Fasoulakis K., Fragkoulis C. et al. Total osseous calcification of the prostate gland. Cureus 2020;12(7):e9239. DOI:10.7759/cureus.9239; Zhao W.P., Li Y.T., Chen J. et al. Prostatic calculi influence the antimicrobial efficacy in men with chronic bacterial prostatitis. Asian J Androl 2012;14(5):715–9. DOI:10.1038/aja.2012.40; Cha W.H., Kim K.H., Seo Y.J. The effect of periurethral prostatic calculi on lower urinary tract symptoms in benign prostatic hyperplasia. Korean J Urol 2008;49(3):237–41. DOI:10.4111/kju.2008.49.3.237; Shoskes D.A., Lee C.T., Murphy D. et al. Incidence and significance of prostatic stones in men with chronic prostatitis/chronic pelvic pain syndrome. Urology 2007;70(2):235–8. DOI:10.1016/j.urology.2007.04.008; Trinchieri A., Perletti G., Magri V. Prostatic calcifications and symptoms of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol Suppl 2010;9:137–8.; Kuei C.H., Liao C.H., Chiang B.J. Significant intravesical prostatic protrusion and prostatic calcification predict unfavorable outcomes of medical treatment for male lower urinary tract symptoms. Urol Sci 2016;27(1):13–6. DOI:10.1016/j.urols.2015.01.003; Jeon H.J., Chung H.C., Song J.M. Effects of residual prostatic calculi on lower urinary tract symptoms after transurethral resection of prostate. Korean J Urol 2005;46:569–73.; https://agx.abvpress.ru/jour/article/view/635
-
19Academic Journal
Συγγραφείς: I. G. Leshchenko, O. I. Bratchikov, A. I. Akimov, Yu. A. Zhilyaeva, И. Г. Лещенко, О. И. Братчиков, А. И. Акимов, Ю. А. Жиляева
Πηγή: Andrology and Genital Surgery; Том 24, № 1 (2023); 138-149 ; Андрология и генитальная хирургия; Том 24, № 1 (2023); 138-149 ; 2412-8902 ; 2070-9781
Θεματικοί όροι: противопоказания к плановым операциям, benign prostatic hyperplasia, contraindications to elective surgery, доброкачественная гиперплазия предстательной железы
Περιγραφή αρχείου: application/pdf
Relation: https://agx.abvpress.ru/jour/article/view/644/511; Урология. Национальное руководство. Под. ред. Н.А. Лопаткина. М.: ГЭОТАР-Медиа, 2009. 1024 с.; Практическая урология. Под. ред. П.В. Глыбочко, Ю.Г. Аляева. М.: ГЭОТАР-Медиа, 2012. 432 с.; Rendon R.A., Mason R.J., Marzouk K. et al. Canadian Urological Association guidelines for prostate screening and early diagnosis. Can Urol Assoc J 2017;11:298–309.; Яковлев О.Г., Лещенко И.Г., Сливкин В.В. Симультанные урологические операции у ветеранов войн. Монография. Самара: Азимут, 2012. 216 c.; Шатохина И.В. Симультанные операции у больных пожилого и старческого возраста с аденомой предстательной железы. Автореф. дисс. … канд. мед. наук. Саратов: 2013. 21 с.; Адлер Ю.П., Маркова Е.В., Грановский Ю.В. Планирование эксперимента при поиске оптимальных условий. М.: Наука; 1976. 279 с.; Саркисян С.А. Многокритериальные задачи принятия решения. В кн.: Теория прогнозирования и принятия решения. Под ред. С.А. Саркисяна. М., 1977. C. 327–345.; Интегративная урология. Руководство для врачей. Под ред. П.В. Глыбочко, Ю.Г. Аляева. М.: Медфорум, 2014. 432 с.; Пушкарь Д.Ю., Раснер П.И. Симптомы нижних мочевых путей и доброкачественная гиперплазия предстательной железы. Урология 2017;3(Suppl):4–18. DOI:10.18565/urol.2017.3-supplement.4-18; Пушкарь Д.Ю., Берников А.Н., Ходырева Л.А. и др. Качество жизни пациентов с симптомами нижних мочевыводящих путей после перенесенной ТУРП по поводу ДГПЖ. Урология 2018;1:53–61. DOI:10.18565/urology.2018.1.53-61; Брискин Б.С. Гериатрические аспекты хирургии. В кн.: Клиническая хирургия: нац. руководство. Под ред. В.С. Савельева, А.И. Кириенко. Т. 1. М.: ГЭОТАР-Медиа, 2008. С. 467–477.; Камалов А.А., Сорокин Н.И., Дзитиев В.К. и др. Ближайшие результаты эндоскопической энуклеации гиперплазии простаты. Материалы XIX Конгресса Российского общества урологов. Ростов-на-Дону, 2019. С. 113–114.; Симбердеев Р.Р., Цариченко Д.Г., Давыдов Д.С. и др. Монополярная энуклиация гиперплазии предстательной железы. Наш опыт. Материалы XIX Конгресса Российского общества урологов. Ростов-на-Дону, 2019. С. 111–112.; Зимичев А.А., Пикалов С.М., Гусев Д.О. и др. Стратегия выбора объема хирургического лечения доброкачественной гиперплазии предстательной железы. Медико-фармацевтический журнал «Пульс» 2020;22(5):115–20. DOI:10.26787/nydha-2686-6838-2020-22-5-115-120; https://agx.abvpress.ru/jour/article/view/644
-
20Academic Journal
Συγγραφείς: E. A. Grekov, I. A. Tyuzikov, A. V. Smirnov, Е. А. Греков, И. А. Тюзиков, А. В. Смирнов
Πηγή: Andrology and Genital Surgery; Том 24, № 1 (2023); 36-47 ; Андрология и генитальная хирургия; Том 24, № 1 (2023); 36-47 ; 2412-8902 ; 2070-9781
Θεματικοί όροι: рак предстательной железы, prostate gland, chronic prostatitis, benign prostatic hyperplasia, prostate cancer, предстательная железа, хронический простатит, доброкачественная гиперплазия предстательной железы
Περιγραφή αρχείου: application/pdf
Relation: https://agx.abvpress.ru/jour/article/view/634/501; Thornton J.W. Evolution of vertebrate steroid receptors from an ancestral estrogen receptor by ligand exploitation and serial genome expansions. Proc Natl Acad Sci U S A 2001;98(10):5671–6. DOI:10.1073/pnas.091553298; McLachlan J.A. Environmental signalling: what embryos and evolution teach us about endocrine disrupting chemicals. Endocr Rev 2001;22(3):319–41. DOI:10.1210/edrv.22.3.0432; Oettel M., Mukhopadhyay A.K. Progesterone: the forgotten hormone in men? Aging Male 2004;7(3):236–57. DOI:10.1080/13685530400004199; Foresta C., Rossato M., Mioni R., Zorzi M. Progesterone induces capacitation in human spermatozoa. Andrologia 1992;24(1):33–5. DOI:10.1111/j.1439-0272.1992.tb02605.x; Pietrobon E.O., Los Monclus M., Alberdi A.J., Fornés M.W. Progesterone receptor availability in mouse spermatozoa during epididymal transit and capacitation: ligand blot detection of progesterone-binding protein. J Androl 2003;24(4):612–20. DOI:10.1002/j.1939-4640.2003.tb02713.x; Baranizadeh K., Mahboobian M.M., Amiri I. et al. Effects of progesterone nanoparticles on the sperm capacitation and acrosome reaction in asthenozoospermia men. Andrologia 2022;54(1):e14258. DOI:10.1111/and.14258; Rasmusson A.M., Pineles S.L., Brown K.D., Pinna G. A role for deficits in GABAergic neurosteroids and their metabolites with NMDA receptor antagonist activity in the pathophysiology of posttraumatic stress disorder. J Neuroendocrinol 2022;34(2):e13062. DOI:10.1111/jne.13062; Baker M.E., Katsu Y. Progesterone: an enigmatic ligand for the mineralocorticoid receptor. Biochem Pharmacol 2020;177:113976. DOI:10.1016/j.bcp.2020.113976; Ohlsson C., Langenskiöld M., Smidfelt K. et al. Low progesterone and low estradiol levels associate with abdominal aortic aneurysms in men. J Clin Endocrinol Metab 2022;107(4):e1413–25. DOI:10.1210/clinem/dgab867; Ghandehari S., Matusov Y., Pepkowitz S. et al. Progesterone in addition to standard of care vs standard of care alone in the treatment of men hospitalized with moderate to severe COVID-19: a randomized, controlled pilot trial. Chest 2021;160(1):74–84. DOI:10.1016/j.chest.2021.02.024; Gadkar-Sable S., Shah C., Rosario G. et al. Progesterone receptors: various forms and functions in reproductive tissues. Front Biosci 2005;10:2118–30. DOI:10.2741/1685.; Shackleton C., Malunowicz E. Apparent pregnene hydroxylation deficiency (APDH): seeking the parentage of an orphan metabolome. Steroids 2003;68(9):707–17. PMID: 14625002. DOI:10.1016/s0039-128x(03)00115-6; Naville D., Keeney D.S., Jenkin G. et al. Regulation of expression of male-specific rat liver microsomal 3 beta-hydroxysteroid dehydrogenase. Mol Endocrinol 1991;5(8):1090–100. DOI:10.1016/s0039- 10.1210/mend-5-8-1090; Zumoff B., Miller L., Levin J. et al. Follicular-phase serum progesterone levels of nonsmoking women do not differ from the levels of nonsmoking men. Steroids 1990;55(12):557–9. DOI:10.1016/0039-128x(90)90052-d; Winkelmann B.R., März W., Boehm B.O. et al. Rationale and design of the LURIC study – a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001;2(Suppl 1):S1–73. DOI:10.1517/14622416.2.1.S1; Arnett-Mansfield R.L., deFazo A., Wain G.V. et al. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 2001;61(11):4576–82. PMID: 11389093.; Lieberman A., Curtis L. In defense of progesterone: a review of the literature. Altern Ther Health Med 2017; 23(6):24–32. PMID: 29055286.; Samadi A., Carlson C.G., Gueorguiev A., Cenedella R.J. Rapid, non-genomic actions of progesterone and estradiol on steady-state calcium and resting calcium influx in lens epithelial cells. Pflugers Arch 2002;444(6):700–9. DOI:10.1007/s00424-002-0889-7; Pedersen S.B., Kristensen K., Richelsen B. Anti-glucocorticoid effects of progesterone in vivo on rat adipose tissue metabolism. Steroids 2003;68(6):543–50. DOI:10.1016/s0039-128х(03)00084-9; Falkenstein E., Tillmann H.-C., Christ M. et al. Multiple actions of steroid hormones – a focus on rapid, nongenomic effects. Pharmacol Rev 2000;52(4):513–55. PMID: 11121509.; Rajaram R.D., Brisken C. Paracrine signaling by progesterone. Mol Cell Endocrinol 2012;357(1–2):80–90. DOI:10.1016/j.mce.2011.09.018; Sciarra A., Innocenzi M., Ravaziol M. et al. [Role of neuroendocrine cells in prostate cancer progression (In Italian)]. Urologia 2011;78(2):126–31. DOI:10.5301/RU.2011.8337; Hermann M., Untergasser G., Rumpold H., Berger P. Aging of the male reproductive system. Exp Gerontol 2000;35(9–10): 1267–79. DOI:10.1016/s0531-5565(00)00159-5; Song L., Shen W., Zhang H. et al. Differential expression of androgen, estrogen, and progesterone receptors in benign prostatic hyperplasia. Bosn J Basic Med Sci 2016;16(3):201–8. DOI:10.17305/bjbms.2016.1209; Chen R., Yu Y., Dong X. Progesterone receptor in the prostate: a potential suppressor for benign prostatic hyperplasia and prostate cancer. J Steroid Biochem Mol Biol 2017;166:91–6. DOI:10.1016/j.jsbmb.2016.04.008; Kaore S.N., Langade D.K., Yadav V.K. et al. Novel actions of progesterone: what we know today and what will be the scenario in the future? J Pharm Pharmacol 2012;64(8):1040–62. DOI:10.1111/j.2042-7158.2012.01464.х; Da Silva M.H.A., De Souza D.B. Current evidence for the involvement of sex steroid receptors and sex hormones in benign prostatic hyperplasia. Res Rep Urol 2019;11:1–8. DOI:10.2147/RRU.S155609.; Fochi R.A., Santos F.C., Goes R.M., Taboga S.R. Progesterone as a morphological regulatory factor of the male and female gerbil prostate. Int J Exp Pathol 2013;94(6):373–86. DOI:10.1111/iep.12050; Yu Y., Yang O., Fazli L. et al. Progesterone receptor expression during prostate cancer progression suggests a role of this receptor in stromal cell differentiation. Prostate 2015;75(10):1043–50. DOI:10.1002/pros.22988; Grindstad T., Andersen S., Al-Saad S. et al. High progesterone receptor expression in prostate cancer is associated with clinical failure. PLoS One 2015;10(2):e0116691. DOI:10.1371/journal.pone.0116691; Grindstad T., Richardsen E., Andersen S. et al. Progesterone receptors in prostate cancer: progesterone receptor B is the isoform associated with disease progression. Sci Rep 2018;8(1):11358. DOI:10.1038/s41598-018-29520-5; Spirina L.V., Kovaleva I.V., Usynin E.A. et al. Progesterone receptor expression in the benign prostatic hyperplasia and prostate cancer tissues, relation with transcription, growth factors, hormone reception and components of the AKT/mTOR signaling pathway. Asian Pac J Cancer Prev 2020;21(2):423–9. DOI:10.31557/APJCP.2020.21.2.423; Bera K.N., Yadav S.K., Prakash O. et al. Immunoexpression of estrogen receptor-β and progesterone receptor in prostate adenocarcinoma, does it inhibit neoplastic proliferation and invasion? Indian J Pathol Microbiol 2020; 63(Supplement): S30–S33. DOI:10.4103/IJPM.IJPM_467_18; Li W., Klein R.J. Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk. Prostate Cancer Prostatic Dis 2021;24(2):492–8. DOI:10.1038/s41391-020-00303-2; Yang M., Li J.C., Tao C. et al. PAQR6 upregulation is associated with AR signaling and unfavorite prognosis in prostate cancers. Biomolecules 2021;11(9):1383. DOI:10.3390/biom11091383; Tao C., Liu W., Yan X. et al. PAQR5 expression is suppressed by TGFβ1 and associated with a poor survival outcome in renal clear cell carcinoma. Front Oncol 2022;11:827344. DOI:10.3389/fonc.2021.827344; Check J.H. The role of progesterone and the progesterone receptor in cancer. Expert Rev Endocrinol Metab 2017;12(3):187–97. DOI:10.1080/17446651.2017.1314783; Pitchford A.G. Gestronol hexanoate (SH582) and benign prostatic hypertrophy. Proc R Soc Med 1972;65(2):128–9. PMID: 4117436.; Ibba A.L. [On the treatment of prostatic adenoma with hydroxyprogesterone caronate (In Italian)]. Osp Ital Chir 1968;19(4):427–42. PMID: 4180617.; Musierowicz A. [Hormonal treatment of prostatic hypertrophy with special reference to the usefulness of gestagens (In Polish)]. Wiad Lek 1974;27(22):1985–8. PMID: 4140619.; Щербаков А.П. Применение прогестерона при аденоме предстательной железы. Урология и нефрология 1978;1:72–6.; Nagel R., Hargenda B. [Treatment of benign prostatic hypertrophy with progestogens including gestonorone caproate. (In Japanese)]. Hinyokika Kiyo 1970;16(9):423–8. PMID: 4097356.; Momose S., Hidaka M., Oota Y., Oomaru K. [The clinical effects of SH 582 (gestonorone caproate) on benign prostatic hypertrophy (In Japanese)]. Hinyokika Kiyo 1970;16(9):551–4. PMID: 4097366.; Tanaka H., Fukushige M., Shiraishi T. [Treatment of prostatic hypertrophy with progestational steroid (gestonorone caproate) (In Japanese)]. Hinyokika Kiyo 1970;16(9):531–50. PMID: 4097365.; Meiraz D., Margolin Y., Lev-Ran A., Lazebnik J. Treatment of benign prostatic hyperplasia with hydroxyprogesterone-caproate: placebo-controlled study. Urology 1977;9(2):144–8. DOI:10.1016/0090-4295(77)90184-4; Schacter L., Rozencweig M., Canetta R. et al. Megestrol acetate: clinical experience. Cancer Treat Rev 1989;16(1):49–63. DOI:10.1016/0305-7372(89)90004-2; Карпушин В.Т., Сапожников В.В. Фонофорез гидроксипрогестерона капроната в лечении больных с аденомой предстательной железы, осложненной дизурией. Вопросы курортологии и физиотерапии. 1981;6:46–9. PMID: 6175097.; Григорьева В.Д., Сапожников В.В., Пономарев Ю.Т. и др. Применение ректального фонофореза гидроксипрогестерона капроната для коррекции эндокринных нарушений у пациентов с аденомой простаты. Вопросы курортологии и физиотерапии 1984;6:29–32. PMID: 6084361.; Onu P.E. Depot medroxyprogesterone in the management of benign prostatic hyperplasia. Eur Urol 1995;28(3):229–35. DOI:10.1159/000475056; Albouy M., Sanquer A., Maynard L., Eun H.M. Efficacies of osaterone and delmadinone in the treatment of benign prostatichyperplasia in dogs. Vet Rec 2008;163(6):179–83. DOI:10.1136/vr.163.6.179; Fujimoto K., Hirao Y., Ohashi Y. et al. The effects of chlormadinone acetate on lower urinary tract symptoms and erectile functions of patients with benign prostatic hyperplasia: a prospective multicenter clinical study. Adv Urol 2013;2013:584678. DOI:10.1155/2013/584678; Li W., Li X., Zhang B. et al. Current progresses and trends in the development of progesterone receptor modulators. Curr Med Chem 2016;23(23):2507–54. DOI:10.2174/0929867323666160428105310; Bouchard P. Selective progesterone receptor modulators: a class with multiple actions and applications in reproductive endocrinology, and gynecology. Gynecol Endocrinol 2014;30(10):683–4. DOI:10.3109/09513590.2014.950647; https://agx.abvpress.ru/jour/article/view/634